<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1801233114
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2023
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Xenor
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        CEFTRIAXONE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        500
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intramuscular use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        powder for solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        10.35
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Pharma International Co." />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Pharma International Co.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 513]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SAUDI ARABIAN DRUG STORE COMPANY
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            PHARMA INTERNATIONAL CO
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J01DD04
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Xenor<sup>&reg;</sup> </strong>is an antibiotic given to adults and children (including newborn babies). It works by killing bacteria that cause infections. It belongs to a group of medicines called cephalosporins.</p><p><strong>Xenor<sup>&reg;</sup> </strong>is used to treat infections of:</p><p>The brain (meningitis).</p><p>The lungs.</p><p>The middle ear.</p><p>The abdomen and abdominal wall (peritonitis).</p><p>The urinary tract and kidneys.</p><p>Bones and joints.</p><p>The skin or soft tissues.</p><p>The blood.</p><p>The heart.</p><p>It can be given:</p><p>To treat specific sexually transmitted infections (gonorrhoea and syphilis).</p><p>To treat patients with low white blood cell counts (neutropenia) who have fever due to bacterial infection.</p><p>To treat infections of the chest in adults with chronic bronchitis.</p><p>To treat Lyme disease (caused by tick bites) in adults and children including newborn babies from 15 days of age.</p><p>To prevent infections during surgery.</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>You must not be given Xenor<sup>&reg;</sup>: </strong></p><p>If you are allergic to ceftriaxone or any of the other ingredients of this medicine.</p><p>If you have had a sudden or severe allergic reaction to penicillin or similar antibiotics (such as cephalosporins, carbapenems or monobactams). The signs include sudden swelling of the throat or face which might make it difficult to breath or swallow, sudden swelling of the hands, feet and ankles, and a severe rash that develops quickly.</p><p>If you are allergic to lidocaine and you are to be given <strong>Xenor<sup>&reg;</sup> </strong>as an injection into a muscle.</p><p><strong>Xenor<sup>&reg;</sup> must not be given to babies if: </strong></p><p>The baby is premature.</p><p>The baby is newborn (up to 28 days of age) and has certain blood problems or jaundice (yellowing of the skin or the whites of the eyes) or is to be given a product that contains calcium into their vein.</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor or pharmacist or nurse before you are given <strong>Xenor<sup>&reg;</sup></strong>:</p><p>If you have recently received or are about to receive products that contain calcium.</p><p>If you have recently had diarrhea after having an antibiotic medicine. You have ever had problems with your gut, in particular colitis (inflammation of the bowel).</p><p>If you have liver or kidney problems.</p><p>If you have gall stones or kidney stones.</p><p>If you have other illnesses, such as haemolytic anaemia (a reduction in your red blood cells that may make your skin pale yellow and cause weakness or breathlessness).</p><p>If you are on a low sodium diet.</p><p>If You experience or have previously experienced a combination of any of the following symptoms: rash, red skin, blistering of the lips, eyes and mouth, skin peeling, high fever, flu-like symptoms, increased levels of liver enzymes seen in blood tests and an increase in a type of white blood cell (eosinophilia) and enlarged lymph nodes (signs of severe skin reactions).</p><p><strong>If you need a blood or urine test </strong></p><p>If you are given <strong>Xenor<sup>&reg;</sup> </strong>for a long time, you may need to have regular blood tests.</p><p><strong>Xenor<sup>&reg;</sup></strong> can affect the results of urine tests for sugar and a blood test known as the Coombs test. If you are having tests:</p><p>Tell the person taking the sample that you have been given <strong>Xenor<sup>&reg;</sup></strong>.</p><p>If you are diabetic or need to have your blood glucose level monitored you should not use certain blood glucose monitoring systems which may estimate blood glucose incorrectly while you are receiving ceftriaxone. If you use such systems check the instructions for use and tell your doctor, pharmacist or nurse.</p><p>Alternative testing methods should be used if necessary.</p><p><strong>Children </strong></p><p>Talk to your doctor or pharmacist or nurse before your child is administered <strong>Xenor<sup>&reg;</sup> </strong>if:</p><p>He/She has recently been given or is to be given a product that contains calcium into their vein.</p><p><strong>Other medicines and Xenor<sup>&reg;</sup> </strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p>In particular, tell your doctor or pharmacist if you are taking any of the following medicines:</p><p>A type of antibiotic called an aminoglycoside.</p><p>An antibiotic called chloramphenicol (used to treat infections, particularly of the eyes).</p><p><strong>Pregnancy, breast-feeding and fertility </strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.</p><p>The doctor will consider the benefit of treating you with <strong>Xenor<sup>&reg;</sup> </strong>against the risk to your baby.</p><p><strong>Driving and using machines </strong></p><p><strong>Xenor<sup>&reg;</sup> </strong>can cause dizziness. If you feel dizzy, do not drive or use any tools or machines.</p><p>Talk to your doctor if you experience these symptoms.</p><p><strong>Important information about some of the ingredients of Xenor<sup>&reg;</sup></strong></p><p><strong>Xenor<sup>&reg;</sup> </strong>contains sodium. This should be taken into consideration in patients on a controlled sodium diet.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Xenor<sup>&reg;</sup> </strong>is usually given by a doctor or nurse. It can be given as</p><p>A drip (intravenous infusion) or as an injection directly into a vein or</p><p>Into a muscle.</p><p><strong>Xenor<sup>&reg;</sup> </strong>is made up by the doctor, pharmacist or nurse and will not be mixed with or given to you at the same time as calcium-containing injections.</p><p><strong>The usual dose:</strong></p><p>Your doctor will decide the correct dose of <strong>Xenor<sup>&reg;</sup> </strong>for you. The dose will depend on the severity and type of infection; whether you are on any other antibiotics; your weight and age; how well your kidneys and liver are working. The number of days or weeks that you are given <strong>Xenor<sup>&reg;</sup> </strong>depends on what sort of infection you have.</p><p><strong>Adults, older people and children aged 12 years and over with a body weight greater than or equal to 50 kilograms (kg):</strong></p><p>1 to 2 g once a day depending on the severity and type of infection. If you have a severe infection, your doctor will give you a higher dose (up to 4 g once a day). If your daily dose is higher than 2 g, you may receive it as a single dose once a day or as two separate doses.</p><p><strong>Newborn babies, infants and children aged 15 days to 12 years with a body weight of less than 50 kg:</strong></p><p>50-80 mg <strong>Xenor<sup>&reg;</sup> </strong>for each kg of the child&rsquo;s body weight once a day depending on the severity and type of infection. If you have a severe infection, your doctor will give you a higher dose up to 100 mg for each kg of body weight to a maximum of 4 g once a day. If your daily dose is higher than 2 g, you may receive it as a single dose once a day or as two separate doses.</p><p>Children with a body weight of 50 kg or more should be given the usual adult dose.</p><p><strong>Newborn babies (0-14 days):</strong></p><p>20-50 mg <strong>Xenor<sup>&reg;</sup> </strong>for each kg of the child&rsquo;s body weight once a day depending on the severity and type of infection.</p><p>The maximum daily dose is not to be more than 50 mg for each kg of the baby&rsquo;s weight.</p><p><strong>People with liver and kidney problems:</strong></p><p>You may be given a different dose to the usual dose. Your doctor will decide how much <strong>Xenor<sup>&reg;</sup> </strong>you will need and will check you closely depending on the severity of the liver and kidney disease.</p><p><strong>Instruction for use:</strong></p><p><strong>Xenor<sup>&reg;</sup> </strong>should not be mixed in the same syringe with any drug other than 1% Lidocaine Hydrochloride solution (for intramuscular injection only).</p><p><strong>Intramuscular injection:</strong> <strong>0.5 g</strong> <strong>Xenor<sup>&reg;</sup> </strong>is dissolved in 2 ml of 1% Lidocaine Hydrochloride solution, or 1 g in 3.5ml of 1% Lidocaine Hydrochloride solution. The solution should be administered by deep intramuscular injection. Dosages greater than 1 g should be divided and injected at more than one site. Solutions in Lidocaine should not be administered intravenously.</p><p><strong>Intravenous injection:</strong> <strong>0.5 g</strong> <strong>Xenor<sup>&reg;</sup> </strong>is dissolved in 5 ml of Water for Injections or 1 g in 10 ml of Water for Injections. The injection should be administered over 5 minutes, directly into the vein or via the tubing of an intravenous infusion.</p><p><strong>Intravenous infusion: </strong>1 g of <strong>Xenor<sup>&reg;</sup> </strong>is dissolved in 20 ml of one of the following calcium-free solutions: sodium chloride 0.9%, sodium chloride 0.45% and dextrose 2.5%, dextrose 5%, dextrose 10%, dextran 70 (6%) in dextrose 5%, hydroxyethly-starch-6 10%, water for injections. The infusion should be administered over at least 30 minutes.</p><p><strong>If you are given more Xenor<sup>&reg;</sup> than you should </strong></p><p>If you accidentally receive more than your prescribed dose, contact your doctor or nearest hospital straight away.</p><p><strong>If you forget to use Xenor<sup>&reg;</sup> </strong></p><p>If you miss an injection, you should have it as soon as possible. However, if it is almost time for your next injection, skip the missed injection. Do not take a double dose (two injections at the same time) to make up for a missed dose.</p><p><strong>If you stop using Xenor<sup>&reg;</sup> </strong></p><p>Do not stop using <strong>Xenor<sup>&reg;</sup></strong> unless your doctor tells you to.</p><p>If you have any further questions on the use of this medicine, ask your doctor or nurse.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>The following side effects may happen with this medicine:</p><p>Treatment with ceftriaxone, particularly in elderly patients with serious kidney or nervous system problems may rarely cause decreased consciousness, abnormal movements, agitation and convulsions.</p><p><strong>Severe allergic reactions (not known, frequency cannot be estimated from the available data) </strong></p><p>If you have a severe allergic reaction, tell a doctor straight away.</p><p>The signs may include:</p><p>Sudden swelling of the face, throat, lips or mouth. This can make it difficult to breathe or swallow.</p><p>Sudden swelling of the hands, feet and ankles.</p><p><strong>Severe skin reactions (not known, frequency cannot be estimated from the available data) </strong></p><p>If you get a severe skin reaction, tell a doctor straight away.</p><p>The signs may include:</p><p>A severe rash that develops quickly, with blisters or peeling of the skin and possibly blisters in the mouth (Stevens-Johnson syndrome and toxic epidermal necrolysis).</p><p>A combination of any of the following symptoms: widespread rash, high body temperature, liver enzyme elevations, blood abnormalities (eosinophilia), enlarged lymph nodes and other body organs involvement (Drug Reaction with Eosinophilia and Systemic Symptoms which is also known as DRESS or drug hypersensitivity syndrome).</p><p>Jarisch-Herxheimer reaction which causes fever, chills, headache, muscle pain, and skin rash that is usually self-limiting. This occurs shortly after starting <strong>Xenor<sup>&reg;</sup></strong> treatment for infections with spirochete such as Lyme disease.</p><p><strong>Other possible side effects: </strong></p><p><strong>Common (may affect up to 1 in 10 people) </strong></p><p>Abnormalities with your white blood cells (such as a decrease of leucocytes and an increase of eosinophils) and platelets (decrease of thrombocytes).</p><p>Loose stools or diarrhea.</p><p>Changes in the results of blood tests for liver functions.</p><p>Rash.</p><p><strong>Uncommon (may affect up to 1 in 100 people) </strong></p><p>Fungal infections (for example, thrush).</p><p>A decrease in the number of white blood cells (granulocytopenia).</p><p>Reduction in number of red blood cells (anaemia).</p><p>Problems with the way your blood clots. The signs may include bruising easily and pain and swelling of your joints.</p><p>Headache.</p><p>Dizziness.</p><p>Feeling sick or being sick.</p><p>Pruritis (itching).</p><p>Pain or a burning feeling along the vein where <strong>Xenor<sup>&reg;</sup></strong> has been given. Pain where the injection was given.</p><p>A high temperature (fever).</p><p>Abnormal kidney function test (blood creatinine increased).</p><p><strong>Rare (may affect up to 1 in 1,000 people) </strong></p><p>Inflammation of the large bowel (colon). The signs include diarrhea, usually with blood and mucus, stomach pain and fever.</p><p>Difficulty in breathing (bronchospasm).</p><p>A lumpy rash (hives) that may cover a lot of your body, feeling itchy and swelling.</p><p>Blood or sugar in your urine.</p><p>Oedema (fluid build-up).</p><p>Shivering.</p><p><strong>Not known (Frequency cannot be estimated from the available data) </strong></p><p>A secondary infection that may not respond to the antibiotic previously prescribed.</p><p>Form of anaemia where red blood cells are destroyed (haemolytic anaemia).</p><p>Severe decrease in white blood cells (agranulocytosis).</p><p>Convulsions.</p><p>Vertigo (spinning sensation).</p><p>Inflammation of the pancreas (pancreatitis). The signs include severe pain in the stomach which spreads to your back.</p><p>Inflammation of the mucus lining of the mouth (stomatitis).</p><p>Inflammation of the tongue (glossitis). The signs include swelling, redness and soreness of the tongue.</p><p>Problems with your gallbladder, which may cause pain, feeling sick and being sick.</p><p>A neurological condition that may occur in neonates with severe jaundice (kernicterus).</p><p>Kidney problems caused by deposits of calcium ceftriaxone. There may be pain when passing water (urine) or low output of urine.</p><p>A false positive result in a Coombs&rsquo; test (a test for some blood problems).</p><p>A false positive result for galactosaemia (an abnormal build up of the sugar galactose).</p><p><strong>Xenor<sup>&reg;</sup></strong> may interfere with some types of blood glucose tests - please check with your doctor.</p><p><strong>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet.</strong></p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the reach and sight of children.</p><p>Do not use <strong>Xenor<sup>&reg; </sup></strong>after the expiry date (EXP) which is stated on the label and the carton.</p><p>The expiry date refers to the last day of that month.</p><p><strong>Xenor<sup>&reg; </sup></strong>powder for solution for injection: Store below 30&deg;C, protected from light.</p><p><strong>After reconstitution &amp; dilution: </strong></p><p>Chemical and physical in-use stability of the reconstituted product has been demonstrated for at least 6 hours at or below 25 &deg;C or 24 hours at 2-8 &deg;C.</p><p>Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is Ceftriaxone (sodium).</p><p>There are no excipients.</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Xenor® 0.5g: An almost white or yellowish, crystalline powder filled in Clear Moulded Glass Vial Type (I) (Size 10 ml), plugged with Bromobutyl Rubber Stopper (Red) & sealed with Aluminum Cap Flip-Off Light Grey Plastic Top, intended for IM or IV injection.
Xenor® 1g: An almost white or yellowish, crystalline powder filled in Clear Moulded Glass Vial Type (I) (Size 10 ml), plugged with Bromobutyl Rubber Stopper (Red) & sealed with Aluminum Cap Flip-Off Green Plastic Top, intended for IM or IV injection.

How supplied 
Xenor® 0.5 g IM/IV: One pack of 10 vials each, containing 0.5 g ceftriaxone (sodium). 
Xenor® 1 g IM/IV: One pack of 10 vials each, containing 1 g ceftriaxone (sodium). 
Xenor® 0.5 g IM: One pack of 1 vial each, containing 0.5 g ceftriaxone (sodium)
+ 1 ampoule 5 ml 1% lidocaine HCl solution.
Xenor® 1 g IM: One pack of 1 vial each, containing 1 g ceftriaxone (Sodium) + 1 ampoule 5 ml 1% lidocaine HCl solution.

To report any side effect(s):
•Saudi Arabia:
The National Pharmacovigilance Center (NPC):
SFDA Call Center: 19999 
E-mail: npc.drug@sfda.gov.sa 
Website: https://ade.sfda.gov.sa
•United Arab of Emirates:
Pharmacovigilance and Medical Device Section
P.O. Box: 1853, Tel: 80011111
Email: pv@mohap.gov.ae
Drug Department, Ministry of Health & Prevention
Dubai-UAE.
•Other GCC States:
Please contact the relevant competent authority.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Pharma International Company</p><p>Amman - Jordan</p><p>Tel: 00962-6-5158890 / 5157893</p><p>Fax: 00962-6-5154753</p><p>Email: marketing@pic-jo.com</p><p>&nbsp;</p><p>This leaflet does not contain all the information about your medicine. If you have any questions or are not sure about anything, ask your doctor or pharmacist.</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in 07/2023


            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يعد <strong>زينور</strong><strong><sup>&reg; </sup></strong>مضاداً حيوياً يتم إعطاؤه للبالغين والأطفال (بما في ذلك الأطفال حديثي الولادة) وهو يعمل عن طريق القضاء على البكتيريا المسببة للالتهابات. وينتمي إلى مجموعة الأدوية التي تعرف بالسيفالوسبورينات.</p><p dir="RTL">يستعمل <strong>زينور</strong><strong><sup>&reg; </sup></strong>لعلاج الالتهابات في أجزاء الجسم التالية:</p><p dir="RTL">الدماغ (التهاب السحايا).</p><p dir="RTL">الرئتين.</p><p dir="RTL">الأذن الوسطى.</p><p dir="RTL">البطن وجداره (التهاب الصفاق).</p><p dir="RTL">الجهاز البولي والكليتين.</p><p dir="RTL">العظام والمفاصل.</p><p dir="RTL">&nbsp;الجلد أو الأنسجة الرخوة.</p><p dir="RTL">الدم.</p><p dir="RTL">القلب.</p><p dir="RTL">ويمكن إعطاؤه في الحالات التالية:</p><p dir="RTL">لعلاج التهابات معينة تنتقل عن طريق الجنس(داء السيلان و داء الزهري).</p><p dir="RTL">لعلاج المرضى الذين يعانون من انخفاض عدد خلايا الدم البيضاء(قلة العدلات) والذين يعانون من حمى نتيجة إصابتهم بالتهاب بكتيري.</p><p dir="RTL">لعلاج التهابات الصدر عند البالغين والذين يعانون من التهاب القصبات المزمن.</p><p dir="RTL">لعلاج مرض لايم (الذي ينتج عن لدغات القرَاد) عند البالغين والأطفال بما في ذلك الأطفال حديثي الولادة من عمر 15 يوم.</p><p dir="RTL">للوقاية من الإصابة بالتهابات خلال العمليات الجراحية.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>يجب</strong><strong> </strong><strong>عدم</strong><strong> </strong><strong>إعطاء</strong><strong> </strong><strong>زينور</strong><strong><sup>&reg;</sup></strong><strong> </strong><strong>في</strong><strong> </strong><strong>الحالات</strong><strong> </strong><strong>التالية</strong><strong>:</strong></p><p dir="RTL">إذا كنت تعاني من تحسس لسيفترياكسون أولأي مكونات أخرى في هذا الدواء.</p><p dir="RTL">إذا عانيت سابقا من تفاعل تحسسي مفاجئ أو حاد عند استعمال البنسيلين أو مضادات حيوية مشابهة (مثل سيفالوسبوينات، كاربابينيمات، مونوباكتام) تتضمن العلامات تورم مفاجئ في الحلق أو الوجه الذي قد يؤدي إلى صعوبة في التنفس أو البلع، تورم مفاجئ في اليدين، القدمين والكاحلين، وطفح حاد الذي يتطور بسرعة.</p><p dir="RTL">إذا كنت تعاني من تحسس لليدوكائين وسيتم إعطاؤك حقنة <strong>زينور</strong><strong><sup>&reg; </sup></strong>في العضل.</p><p dir="RTL"><strong>يجب</strong><strong> </strong><strong>عدم</strong><strong> </strong><strong>إعطاء</strong><strong> </strong><strong>زينور</strong><strong><sup>&reg; </sup></strong><strong>للأطفال</strong><strong> </strong><strong>في</strong><strong> </strong><strong>الحالات</strong><strong> </strong><strong>التالية</strong><strong>:</strong></p><p dir="RTL">للأطفال الخدج.</p><p dir="RTL">للأطفال حديثي الولادة (الذين تبلغ أعمارهم 28 يوم أو أقل) والذين يعانون من مشاكل معينة في الدم أو يرقان(إصفرارالجلد أو المنطقة البيضاء في العيون) أو الذين سيتم إعطاؤهم مستحضر يحتوي على الكالسيوم في الوريد.</p><p dir="RTL"><strong>الاحتياطات</strong><strong> </strong><strong>والمحاذير</strong></p><p dir="RTL">تحدث مع الطبيب أو الصيدلي أو الممرض قبل إعطائك <strong>زينور</strong><strong><sup>&reg;</sup></strong>:</p><p dir="RTL">إذا تم إعطاؤك مؤخرا أو على وشك إعطائك مستحضر يحتوي على الكالسيوم.</p><p dir="RTL">إذا عانيت مؤخراً من الإسهال عند استعمال مضادات حيوية. أو عانيت في السابق من مشاكل في المعي، بشكل خاص التهاب القولون (التهاب الأمعاء).</p><p dir="RTL">إذا كنت تعاني من مشاكل في الكبد أو الكلى.</p><p dir="RTL">إذا كنت تعاني من تكون الحصى في المرارة أو الكلى.</p><p dir="RTL">إذا كنت تعاني من مرض آخر مثل فقر الدم الانحلالي (انخفاض في عدد خلايا الدم الحمراء الذي يجعل الجلد شاحبا أصفر اللون ويسبب الشعور بالضعف وصعوبة في التنفس) .</p><p dir="RTL">إذا كنت تخضع لنظام غذائي قليل الصوديوم.</p><p dir="RTL">إذا كنت تعاني أو عانيت سابقا من أي من الأعراض التالية: طفح جلدي، احمرار الجلد، تنفطات في الشفتين، العيون و الفم، ارتفاع كبير في درجة حرارة الجسم، أعراض تشبه الإنفلونزا، زيادة مستوى إنزيمات الكبد عند إجراء فحص الدم و ازدياد عدد نوع من خلايا الدم البيضاء (فرط الحمضات) وتضخم في الغدد الليمفاوية (علامات لحدوث تفاعلات جلدية حادة).</p><p dir="RTL"><strong>إذا</strong><strong> </strong><strong>كنت</strong><strong> </strong><strong>بحاجة</strong><strong> </strong><strong>للقيام</strong><strong> </strong><strong>بعمل</strong><strong> </strong><strong>فحوصات</strong><strong> </strong><strong>دم</strong><strong> </strong><strong>أو</strong><strong> </strong><strong>بول</strong></p><p dir="RTL">إذا تم إعطاؤك <strong>زينور</strong><strong><sup>&reg; </sup></strong>لفترة طويلة، قد تحتاج للقيام بعمل فحوصات دم دورية. قد يؤثر <strong>زينور</strong><strong><sup>&reg; </sup></strong>على نتائج فحوصات البول المتعلقة بوجود السكر وفحص دم يعرف بفحص كومب .إذا كنت ستخصع لفحوصات:</p><p dir="RTL">أخبر الشخص الذي سيأخذ منك العينة أنه تم إعطاؤك <strong>زينور</strong> .<strong><sup>&reg;</sup></strong></p><p dir="RTL">إذا كنت تعاني من داء السكري أو تحتاج لمراقبة مستوى الجلوكوز في الدم، يجب عدم استخدام بعض أنظمة مراقبة مستوى السكر في الدم حيث قد تكون النتائج غير صحيحة أثناء فترة إعطائك سيفترياكسون.</p><p dir="RTL">إذ كنت تستعمل مثل هذه الأنظمة تأكد من تعليمات الاستخدام و أخبر الطبيب، الصيدلي أو الممرض. يجب استخدام طرق بديلة للفحص إذا ادعت الحاجة.</p><p dir="RTL"><strong>الأطفال</strong></p><p dir="RTL">تحدث مع الطبيب أو الصيدلي أو الممرض قبل إعطاء <strong>زينور</strong><strong><sup>&reg; </sup></strong>لطفلك.</p><p dir="RTL">إذا تم إعطاؤه/إعطاؤها مؤخرا أو سيتم إعطاؤهم مستحضر يحتوي على الكالسيوم في الوريد.</p><p dir="RTL"><strong>أدوية</strong><strong> </strong><strong>أخرى</strong><strong> </strong><strong>مع</strong><strong> </strong><strong>زينور</strong><strong><sup> &reg;</sup></strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول، تناولت مؤخراً أو من الممكن أن تتناول أي أدوية أخرى.</p><p dir="RTL">بشكل خاص، أخبر الطبيب أو الصيدلي إذا كنت تتناول أي من الأدوية التالية:</p><p dir="RTL">نوع من المضادات الحيوية يعرف بالأمينوجلايكوسايد.</p><p dir="RTL">مضاد حيوي يعرف بكلورامفينيكول (يستعمل لعلاج الالتهابات، خصوصا في العيون).</p><p dir="RTL"><strong>الحمل</strong><strong> </strong><strong>والرضاعة</strong><strong> </strong><strong>الطبيعية</strong><strong> </strong><strong>و</strong><strong> </strong><strong>الخصوبة</strong></p><p dir="RTL">إذا كنت حاملا أو ترضعين، تعتقدين أنك حاملا أو تخططين للحمل، استشيري الطبيب قبل استعمال هذا الدواء.</p><p dir="RTL">سيأخذ الطبيب بعين الاعتبار الفوائد المرجوة من علاجك باستعمال <strong>زينور</strong><strong><sup>&reg; </sup></strong>مقابل الخطورة المتوقعة على الطفل.</p><p dir="RTL"><strong>القيادة</strong><strong> </strong><strong>و</strong><strong> </strong><strong>استخدام</strong><strong> </strong><strong>الآلات</strong></p><p dir="RTL">قد يسبب <strong>زينور</strong><strong><sup>&reg; </sup></strong>شعور بالدوار. إذا شعرت بالدوار، تجنب القيادة أو استخدام الأدوات أو الآلات .تحدث مع الطبيب إذا عانيت من هذه الأعراض.</p><p dir="RTL"><strong>معلومات</strong><strong> </strong><strong>مهمة</strong><strong> </strong><strong>حول</strong><strong> </strong><strong>بعض</strong><strong> </strong><strong>مكونات</strong><strong> </strong><strong>زينور</strong><strong><sup>&reg;</sup></strong></p><p dir="RTL">يحتوي<strong> </strong><strong>زينور</strong><strong><sup>&reg;</sup></strong><strong> </strong>على الصوديوم. يجب أخذ ذلك بعين الاعتبار عند المرضى الذين يتبعون نظام غذائي مضبوط الصوديوم.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يتم إعطاء <strong>زينور</strong><strong><sup>&reg; </sup></strong>عادة من قبل الطبيب أو الممرض .ومن الممكن إعطائه:</p><p dir="RTL">على شكل تسريب (حقن بطيء في الوريد) أو كحقن مباشر في الوريد أو</p><p dir="RTL">حقن مباشر في العضل.</p><p dir="RTL">يتم تحضير <strong>زينور</strong><strong><sup>&reg; </sup></strong>بواسطة الطبيب، الصيدلي أو الممرض ولن يتم مزجه أو إعطاؤه بنفس الوقت مع حقن تحتوي على الكالسيوم.</p><p dir="RTL"><strong>الجرعة</strong><strong> </strong><strong>المعتادة</strong><strong>:</strong></p><p dir="RTL">سيقرر الطبيب الجرعة المناسبة لك من <strong>زينور</strong><strong><sup>&reg;</sup></strong><strong> </strong>وستعتمد الجرعة على شدة ونوع الالتهاب، إذا كنت تتناول مضادات حيوية أخرى، وزنك وعمرك، و صحة وظيفة الكلى و الكبد لديك .تعتمد مدة استعمال <strong>زينور</strong><strong><sup>&reg; </sup></strong>على نوع الالتهاب.</p><p dir="RTL"><strong>البالغون،</strong><strong> </strong><strong>كبار</strong><strong> </strong><strong>السن</strong><strong> </strong><strong>والأطفال</strong><strong> </strong><strong>الذين</strong><strong> </strong><strong>تبلغ</strong><strong> </strong><strong>أعمارهم</strong><strong> 12 </strong><strong>عاماً</strong><strong> </strong><strong>و</strong><strong> </strong><strong>أكثر</strong><strong> </strong><strong>وتزيد</strong><strong> </strong><strong>أوزانهم</strong><strong> </strong><strong>عن</strong><strong> </strong><strong>أو</strong><strong> </strong><strong>تساوي</strong><strong> 50 </strong><strong>كغم</strong><strong>:</strong></p><p dir="RTL">1-2 غم مرة واحدة يوميا بالاعتماد على شدة ونوع الالتهاب. إذا كنت تعاني من التهاب حاد، سيعطيك الطبيب جرعة أعلى (تصل لغاية 4 غم مرة واحدة يومياً). إذا كانت جرعتك اليومية أعلى من 2 غم، قد يتم إعطاؤها كجرعة واحدة مرة واحدة يومياً أو كجرعتين منفصلتين.</p><p dir="RTL"><strong>الأطفال</strong><strong> </strong><strong>حديثي</strong><strong> </strong><strong>الولادة،</strong><strong> </strong><strong>الرضع</strong><strong> </strong><strong>و</strong><strong> </strong><strong>الأطفال</strong><strong> </strong><strong>الذين</strong><strong> </strong><strong>تتراوح</strong><strong> </strong><strong>أعمارهم</strong><strong> </strong><strong>بين</strong><strong> 15 </strong><strong>يوم</strong><strong> </strong><strong>إلى</strong><strong> 12 </strong><strong>عاما</strong><strong> </strong><strong>وأوزانهم</strong><strong> </strong><strong>أقل</strong><strong> </strong><strong>من</strong><strong> 50 </strong><strong>كغم</strong><strong>:</strong></p><p dir="RTL">50-80 ملغم من <strong>زينور</strong><strong><sup>&reg;</sup></strong><strong> </strong>لكل كغم من وزن الطفل مرة واحدة يوميا بالاعتماد على شدة ونوع الالتهاب .إذا كنت تعاني من التهاب حاد، سيعطيك الطبيب جرعة أعلى تصل لغاية 100 ملغم لكل كغم من وزن الجسم لتصل الجرعة القصوى إلى 4 غم مرة واحدة يوميا. إذا كانت جرعتك اليومية أعلى من 2 غم، قد يتم إعطاؤها كجرعة واحدة مرة واحدة يومياً أو كجرعتين منفصلتين.</p><p dir="RTL">الأطفال الذين تبلغ أوزانهم 50 كغم أو أكثر يجب إعطاؤهم الجرعة المعتادة للبالغين.</p><p dir="RTL"><strong>الأطفال</strong><strong> </strong><strong>حديثي</strong><strong> </strong><strong>الولادة</strong><strong> (0-14 </strong><strong>يوم</strong><strong>):</strong></p><p dir="RTL">20-50 ملغم من <strong>زينور</strong><strong><sup>&reg; </sup></strong>لكل كغم من وزن الطفل مرة واحدة يوميا بالاعتماد على شدة ونوع الالتهاب.</p><p dir="RTL">يجب أن لا تزيد الجرعة اليومية القصوى عن 50 ملغم لكل كغم من وزن الطفل.</p><p dir="RTL"><strong>الأشخاص</strong><strong> </strong><strong>الذين</strong><strong> </strong><strong>يعانون</strong><strong> </strong><strong>من</strong><strong> </strong><strong>مشاكل</strong><strong> </strong><strong>في</strong><strong> </strong><strong>الكبد</strong><strong> </strong><strong>والكلى</strong></p><p dir="RTL">قد يتم إعطاؤك جرعة مختلفة عن الجرعة المعتادة .سيقرر الطبيب الجرعة التي تحتاجها من <strong>زينور</strong><strong><sup>&reg;</sup></strong><strong> </strong>وسيراقبك جيدا بالاعتماد على شدة مرض الكبد والكلى لديك.</p><p dir="RTL"><strong>تعليمات</strong><strong> </strong><strong>الاستعمال</strong><strong>:</strong></p><p dir="RTL">يجب عدم خلط <strong>زينور</strong><strong><sup>&reg;</sup></strong> في نفس الحقنة مع دواء آخر باستثناء محلول 1% ليدوكائين هيدروكلوريد (للحقن العضلي فقط).</p><p dir="RTL"><strong>الحقن</strong><strong> </strong><strong>العضلي</strong><strong>:</strong> يتم إذابة <strong>زينور</strong><sup>&reg; </sup>0.5 غم في 2 مل من محلول 1% ليدوكائين هيدروكلوريد، أو 1 غم في 3.5 مل من محلول 1% ليدوكائين هيدروكلوريد، يجب إعطاء المحلول عن طريق الحقن العميق داخل العضل. يجب أن يتم تقسيم الجرعات التي تزيد عن 1 غم و حقنها في أكثر من موقع واحد. يجب عدم إعطاء المحاليل المحضرة باستعمال الليدوكائين عن طريق الحقن الوريدي.</p><p dir="RTL"><strong>الحقن</strong><strong> </strong><strong>الوريدي</strong><strong>:</strong> يتم إذابة <strong>زينور</strong><strong><sup>&reg;</sup></strong>0.5&nbsp; غم في 5 مل من الماء المعقم للحقن أو 1 غم في 10 مل من الماء المعقم للحقن. يجب إعطاء الحقنة لمدة 5 دقائق، مباشرة داخل الوريد أو عن طريق الحقن الوريدي البطئ باستعمال أنبوب الحقن.</p><p dir="RTL"><strong>الحقن</strong><strong> </strong><strong>الوريدي</strong><strong> </strong><strong>البطئ</strong><strong>:</strong> يتم إذابة <strong>زينور</strong><strong><sup>&reg;</sup></strong> 1 غم في 20 مل من أحد المحاليل التالية و الخالية من الكالسيوم: (كلوريد الصوديوم 0.9%، كلوريد الصوديوم 0.45% و ديكستروز 2.5%، ديكستروز 5%، ديكستروز10%، ديكستران 70 (6%) في ديكستروز 5%، هيدروكسي إيثيلِ-النَّشا-6 10%، ماء معقم للحقن).</p><p dir="RTL"><strong>إذا</strong><strong> </strong><strong>تم</strong><strong> </strong><strong>إعطاؤك</strong><strong> </strong><strong>زينور</strong><strong><sup>&reg;</sup></strong><strong> </strong><strong>أكثر</strong><strong> </strong><strong>مما</strong><strong> </strong><strong>يجب</strong></p><p dir="RTL">إذا تم إعطاؤك عن طريق الخطأ أكثر من الجرعة الموصوفة، اتصل مع الطبيب أو أقرب مستشفى فورا.</p><p dir="RTL"><strong>إذا</strong><strong> </strong><strong>نسيت</strong><strong> </strong><strong>أخذ</strong><strong> </strong><strong>جرعة</strong><strong> </strong><strong>زينور</strong><strong> </strong><strong><sup>&reg;</sup></strong></p><p dir="RTL">إذا نسيت أخذ جرعة، يجب أخذها في أقرب وقت ممكن لكن، إذا اقترب موعد الجرعة التالية، اترك الجرعة المنسية. لا تتناول جرعة مضاعفة (حقنتين في نفس الوقت) لتعويض الجرعة المنسية.</p><p dir="RTL"><strong>إذا</strong><strong> </strong><strong>توقفت</strong><strong> </strong><strong>عن</strong><strong> </strong><strong>استعمال</strong><strong> </strong><strong>زينور</strong><strong><sup>&reg;</sup></strong></p><p dir="RTL">لا تتوقف عن استعمال <strong>زينور</strong><strong><sup>&reg;</sup></strong><strong> </strong>ما لم يخبرك الطبيب بذلك.</p><p dir="RTL">إذا كان لديك أية أسئلة إضافية عن استعمال هذا الدواء، اسأل طبيبك أو الممرض.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، قد يسبب هذا الدواء آثار جانبية، على الرغم من عدم حدوثها لدى الجميع.</p><p dir="RTL">من الممكن حدوث الآثار الجانبية التالية عند استعمال هذا الدواء:</p><p dir="RTL">قد يسبب العلاج باستعمال سيفترياكسون بشكل نادر، خاصة عند المرضى كبار السن الذين يعانون من مشاكل خطيرة في الكلى أو مشاكل في الجهاز العصبي انخفاض الوعي، حركات غير طبيعية، هياج و تشنجات.</p><p dir="RTL"><strong>تفاعلات</strong><strong> </strong><strong>تحسسية</strong><strong> </strong><strong>حادة</strong><strong> (</strong><strong>غير</strong><strong> </strong><strong>معروفة،</strong><strong> </strong><strong>لا</strong><strong> </strong><strong>يمكن</strong><strong> </strong><strong>تقدير</strong><strong> </strong><strong>تكرار</strong><strong> </strong><strong>حدوثها</strong><strong> </strong><strong>من</strong><strong> </strong><strong>المعلومات</strong><strong> </strong><strong>المتوفرة</strong><strong>)</strong></p><p dir="RTL">إذا حدث لديك تفاعل تحسسي حاد، أخبر الطبيب فوراً.</p><p dir="RTL">قد تتضمن العلامات:</p><p dir="RTL">تورم مفاجئ في الوجه: الحلق، الشفاه أو الفم وهذا قد يسبب صعوبة في التنفس أو البلع.</p><p dir="RTL">تورم مفاجئ في اليدين، القدمين و الكاحلين.</p><p dir="RTL"><strong>تفاعلات</strong><strong> </strong><strong>جلدية</strong><strong> </strong><strong>حادة</strong><strong> (</strong><strong>غير</strong><strong> </strong><strong>معروفة،</strong><strong> </strong><strong>لا</strong><strong> </strong><strong>يمكن</strong><strong> </strong><strong>تقدير</strong><strong> </strong><strong>تكرار</strong><strong> </strong><strong>حدوثها</strong><strong> </strong><strong>من</strong><strong> </strong><strong>المعلومات</strong><strong> </strong><strong>المتوفرة</strong><strong>)</strong></p><p dir="RTL">إذا حدث لديك تفاعل جلدي حاد، أخبر الطبيب فوراً.</p><p dir="RTL">قد تتضمن العلامات:</p><p dir="RTL">تفاعل حاد يتطور بسرعة، مع ظهور تنفطات أو تقشر الجلد ومن الممكن ظهور تنفطات داخل الفم(متلازمة ستيفن جونسون و تحلل نخزي سام في البشرة).</p><p dir="RTL">ظهور أي من الأعراض التالية معا: طفح جلدي واسع الانتشار، ارتفاع كبير في درجة حرارة الجسم، زيادة مستوى إنزيمات الكبد، اضطرابات في الدم (فرط الحمضات)، تضخم في الغدد الليمفاوية و في أعضاء الجسم الأخرى (تفاعل ناتج عن استعمال الدواء مع ظهور فرط الحمضات وأعراض جهازية أو متلازمة فرط التحسس الدوائية)</p><p dir="RTL">تفاعل جاريش-هريكسايمر و الذي يسبب حمى، قشعريرة، صداع، ألم في العضلات و طفح جلدي والذي يعود إلى حالته الطبيعية لوحده. يحدث هذا بعد البدء باستعمال <strong>زينور</strong><strong><sup>&reg;</sup></strong> بفترة قصيرة لعلاج الالتهابات الناتجة عن البكتيريا الملتوية مثل مرض لايم.</p><p dir="RTL"><strong>آثار</strong><strong> </strong><strong>جانبية</strong><strong> </strong><strong>محتملة</strong><strong> </strong><strong>أخرى</strong><strong>:</strong></p><p dir="RTL"><strong>شائعة</strong><strong> (</strong><strong>قد</strong><strong> </strong><strong>تؤثر</strong><strong> </strong><strong>على</strong><strong> 1 </strong><strong>أو</strong><strong> </strong><strong>أقل</strong><strong> </strong><strong>من</strong><strong> </strong><strong>كل</strong><strong> 10 </strong><strong>أشخاص</strong><strong>)</strong></p><p dir="RTL">اضطرابات في خلايا الدم البيضاء (مثل انخفاض عدد الخلايا البيضاء وزيادة في عدد الحمضات) والصفيحات (انخفاض عدد الصفيحات الدموية).</p><p dir="RTL">براز لين أو إسهال.</p><p dir="RTL">تغيرات في نتائج فحوصات الدم المتعلقة بوظائف الكبد.</p><p dir="RTL">طفح.</p><p dir="RTL"><strong>غير</strong><strong> </strong><strong>شائعة</strong><strong> (</strong><strong>قد</strong><strong> </strong><strong>تؤثر</strong><strong> </strong><strong>على</strong><strong> 1 </strong><strong>أو</strong><strong> </strong><strong>أقل</strong><strong> </strong><strong>من</strong><strong> </strong><strong>كل</strong><strong> 100 </strong><strong>شخص</strong><strong>)</strong></p><p dir="RTL">التهابات فطرية (مثل القلاع).</p><p dir="RTL">انخفاض في عدد خلايا الدم البيضاء (قلة المحببات).</p><p dir="RTL">انخفاض في عدد خلايا الدم الحمراء (فقر الدم).</p><p dir="RTL">مشاكل في طريقة تجلط الدم. قد تتضمن العلامات تكون الكدمات بسهولة و ألم و تورم في المفاصل.</p><p dir="RTL">صداع.</p><p dir="RTL">شعور بالدوار.</p><p dir="RTL">شعور بالغثيان أو القيء.</p><p dir="RTL">حكة.</p><p dir="RTL">ألم أو شعور بالحرقة على طول الوريد الذي تم حقن <strong>زينور</strong><strong><sup>&reg;</sup></strong><strong> </strong>داخله. ألم في مكان الحقن.</p><p dir="RTL">ارتفاع درجة حرارة الجسم (حمى).</p><p dir="RTL">نتائج غير طبيعية لفحوصات وظائف الكلى (ارتفاع مستوى الكرياتينين في الدم).</p><p dir="RTL"><strong>نادرة</strong><strong> (</strong><strong>قد</strong><strong> </strong><strong>تؤثر</strong><strong> </strong><strong>على</strong><strong> 1 </strong><strong>أو</strong><strong> </strong><strong>أقل</strong><strong> </strong><strong>من</strong><strong> </strong><strong>كل</strong><strong> 1000 </strong><strong>شخص</strong><strong>)</strong></p><p dir="RTL">التهاب الأمعاء الغليظة (القولون) تتضمن العلامات إسهال، عادة يرافقه ظهور الدم ومخاط، ألم في المعدة وحمى.</p><p dir="RTL">صعوبة في التنفس (تشنج قصبي).</p><p dir="RTL">طفح يرافقه ظهور كتل على الجلد (شرى) الذي قد يغطى معظم مناطق الجسم، شعور بالحكة وتورم.</p><p dir="RTL">ظهور الدم أو السكر في فحص البول.</p><p dir="RTL">وذمة (تجمع السوائل).</p><p dir="RTL">قشعريرة.</p><p dir="RTL"><strong>غير</strong><strong> </strong><strong>معروفة</strong><strong> (</strong><strong>لا</strong><strong> </strong><strong>يمكن</strong><strong> </strong><strong>تقدير</strong><strong> </strong><strong>تكرار</strong><strong> </strong><strong>حدوثها</strong><strong> </strong><strong>من</strong><strong> </strong><strong>المعلومات</strong><strong> </strong><strong>المتوفرة</strong><strong>)</strong></p><p dir="RTL">التهاب ثانوي الذي لم يستجب للمضاد الحيوي الموصوف سابقاً.</p><p dir="RTL">شكل من أشكال فقر الدم حيث يحدث فيه تلف في خلايا الدم الحمراء (فقر الدم الانحلالي).</p><p dir="RTL">انخفاض حاد في عدد خلايا الدم البيضاء (داء فقد الكريات المحببة).</p><p dir="RTL">تشنجات.</p><p dir="RTL">رنح (شعور بالدوران).</p><p dir="RTL">التهاب البنكرياس .تتضمن العلامات ألم حاد في المعدة الذي ينتشر إلى منطقة الظهر.</p><p dir="RTL">التهاب البطانة المخاطية للفم (التهاب الفم).</p><p dir="RTL">التهاب اللسان، تتضمن العلامات تورم، احمرار و تقرح اللسان.</p><p dir="RTL">مشاكل في المرارة، الذي قد يسبب ألم، شعور بالغثيان والقيء.</p><p dir="RTL">حالة عصبية قد تحدث عند الأطفال حديثي الولادة والذين يعانون من يرقان حاد (يرقان نووي).</p><p dir="RTL">مشاكل في الكلى ناتجة عن ترسب سيفترياكسون الكالسيوم .قد يحدث شعور بالألم عند التبول أو انخفاض كمية البول.</p><p dir="RTL">نتائج إيجابية خاطئة لفحص كومب (فحص لبعض مشاكل الدم).</p><p dir="RTL">نتائج إيجابية خاطئة لفحص وجود سكر اللبن في الدم (تراكم غير طبيعي لسكر اللبن في الدم).</p><p dir="RTL">قد يؤثر <strong>زينور</strong><strong><sup>&reg;</sup></strong><strong> </strong>على نتائج بعض أنواع فحوصات سكر الدم - الرجاء تأكد من الطبيب.</p><p dir="RTL"><strong>إإذا</strong><strong> </strong><strong>حصل</strong><strong> </strong><strong>لديك</strong><strong> </strong><strong>أي</strong><strong> </strong><strong>آثار</strong><strong> </strong><strong>جانبية،</strong><strong> </strong><strong>هذا</strong><strong> </strong><strong>يتضمن</strong><strong> </strong><strong>أي</strong><strong> </strong><strong>آثار</strong><strong> </strong><strong>جانبية</strong><strong> </strong><strong>غير</strong><strong> </strong><strong>المذكورة</strong><strong> </strong><strong>في</strong><strong> </strong><strong>هذه</strong><strong> </strong><strong>النشرة</strong><strong>. </strong><strong>تحدث</strong><strong> </strong><strong>مع</strong><strong> </strong><strong>طبيبك،</strong><strong> </strong><strong>الصيدلي</strong><strong> </strong><strong>أو</strong><strong> </strong><strong>الممرض</strong><strong>.</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يحفظ بعيدا عن متناول الأطفال و نظرهم.</p><p dir="RTL">لا تستخدم <strong>زينور</strong><strong><sup>&reg;</sup></strong><strong> </strong>بعد تاريخ انتهاء الصلاحية (EXP) المذكورعلى الملصق و العلبة الخارجية.</p><p dir="RTL">تاريخ الانتهاء يشير إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">مسحوق <strong>زينور</strong><strong><sup>&reg;</sup></strong><strong> </strong>لتحضير محلول للحقن: يحفظ بدرجة حرارة دون 30 &deg;م، بعيدا عن الضوء.</p><p dir="RTL"><strong>بعد</strong><strong> </strong><strong>التحضير</strong><strong> </strong><strong>و</strong><strong> </strong><strong>التخفيف</strong><strong>:</strong></p><p dir="RTL">أظهرت دراسات الثبوتية أن المحلول المحضر يبقى ثابتا من الناحية الكيميائية و الفيزيائية لمدة لا تقل عن 6 ساعات عند حفظه في درجة حرارة 25 &deg;م أو أقل أو لمدة 24 ساعة عند حفظه في درجة حرارة تتراوح بين 2-8 &deg;م .</p><p dir="RTL">يجب أن لا يتم التخلص من الأدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد مطلوبة .وسوف تساعد هذه التدابير في حماية البيئة.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعالة هي سيفترياكسون (صوديوم).</p><p dir="RTL">لا يوجد مكونات أخرى في هذا الدواء.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>زينور</strong><strong><sup>&reg;</sup></strong><strong> 0.5 </strong><strong>غم</strong><strong>: </strong>مسحوق بلوري أبيض أو مصفراللون، معبأ في عبوة زجاج شفاف من النوع (I) (حجم 01 مل) ذات غطاء مطاطي من البروموبيوتيل (أحمر اللون) ومختومة بغطاء من الألومنيوم، و يعلوه غطاء بلاستيكي رمادي فاتح اللون، معدة للحقن العضلي أو الوريدي.</p><p dir="RTL"><strong>زينور</strong><strong><sup>&reg;</sup></strong><strong> 1 </strong><strong>غم</strong><strong>: </strong>مسحوق بلوري أبيض أو مصفراللون، معبأ في عبوة زجاج شفاف من النوع (I) (حجم 01 مل) ذات غطاء مطاطي من البروموبيوتيل (أحمر اللون) ومختومة بغطاء من الألومنيوم، و يعلوه غطاء بلاستيكي أخضر اللون، معدة للحقن العضلي أو الوريدي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>العبوات</strong></p><p dir="RTL"><strong>زينور</strong><strong><sup>&reg;</sup></strong><strong> 0.5 </strong><strong>غم</strong><strong> </strong><strong>حقن</strong><strong> </strong><strong>عضلي</strong><strong>/</strong><strong>وريدي</strong><strong>: </strong>كل علبة تحتوي على 10عبوات. في كل عبوة 0.5 غم سيفترياكسون (صوديوم).</p><p dir="RTL"><strong>زينور</strong><strong>1 <sup>&reg;</sup></strong><strong>غم</strong><strong> </strong><strong>حقن</strong><strong> </strong><strong>عضلي</strong><strong>/</strong><strong>وريدي</strong><strong>: </strong>كل علبة تحتوي على 10عبوات .في كل عبوة 1 غم سيفترياكسون (صوديوم).</p><p dir="RTL"><strong>زينور</strong><strong><sup>&reg;</sup></strong><strong> 0.5 </strong><strong>غم</strong><strong> </strong><strong>حقن</strong><strong> </strong><strong>عضلي</strong><strong>:</strong> كل علبة تحتوي على عبوة واحدة . في كل عبوة 0.5 غم سيفترياكسون(صوديوم) +أمبولة واحدة 5 مل ليدوكائين هيدروكلوريد.</p><p dir="RTL"><strong>زينور</strong><strong><sup>&reg;</sup></strong> <strong>1 </strong><strong>غم</strong><strong> </strong><strong>حقن</strong><strong> </strong><strong>عضلي</strong><strong>:</strong> كل علبة تحتوي على عبوة واحدة . في كل عبوة 1 غم سيفترياكسون(صوديوم)+أمبولة واحدة 5 مل ليدوكائين هيدروكلوريد.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>للإبلاغ</strong><strong> </strong><strong>عن</strong><strong> </strong><strong>أي</strong><strong> </strong><strong>أعراض</strong><strong> </strong><strong>جانبية</strong><strong>:</strong></p><p dir="RTL"><strong>&nbsp;&bull;</strong><strong>المملكة</strong><strong> </strong><strong>العربية</strong><strong> </strong><strong>السعودية</strong><strong>:</strong></p><p dir="RTL">المركز الوطني للتيقظ الدوائي:</p><p dir="RTL">مركز الاتصال الموحد: 19999</p><p dir="RTL">البريد الالكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">الموقع الالكتروني: https://ade.sfda.gov.sa</p><p dir="RTL"><strong>&bull;</strong><strong>الإمارات</strong><strong> </strong><strong>العربية</strong><strong> </strong><strong>المتحدة</strong><strong>:</strong></p><p dir="RTL">قسم اليقظة الدوائية والأجهزة الطبية</p><p dir="RTL">ص.ب: 1853، هاتف: 80011111</p><p dir="RTL">البريد الإلكتروني: pv@mohap.gov.ae</p><p dir="RTL">قسم الأدوية، وزارة الصحة و وقاية المجتمع</p><p dir="RTL">دبي- الإمارات العربية المتحدة.</p><p dir="RTL"><strong>&bull; </strong><strong>دول</strong><strong> </strong><strong>الخليج</strong><strong> </strong><strong>العربي</strong><strong> </strong><strong>الأخرى</strong><strong>:</strong></p><p dir="RTL">الرجاء الاتصال بالجهات الوطنية في كل دولة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">الشركة الدولية للدواء</p><p dir="RTL">عمان &ndash; الأردن</p><p dir="RTL">الهاتف: 5157893 / 5158890 - 6 - 00962&nbsp;</p><p dir="RTL">فاكس: 5154753 - 6 -&nbsp; 00962</p><p dir="RTL">البريد الإلكتروني: marketing@pic-jo.com</p><p dir="RTL">&nbsp;</p><p dir="RTL">هذه النشرة لا تحتوي على جميع المعلومات عن المستحضر. إذا كان لديك أية أسئلة أو لم تكن متأكدا من أي شيء، اسأل طبيبك أو الصيدلي.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تم تنقيح هذه النشرة في 07/ 2023
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Xenor® 0.5g Powder for Solution for Intramuscular/Intravenous Injection.
Xenor® 1g Powder for Solution for Intramuscular/Intravenous Injection.
Xenor® 0.5g Powder for solution for Intramuscular Injection.
Xenor® 1g Powder for solution for Intramuscular Injection.
Ceftriaxone (sodium) 0.5g Powder for Solution for Intramuscular/Intravenous Injection.
Ceftriaxone (sodium) 1g Powder for Solution for Intramuscular/Intravenous Injection.
Ceftriaxone (sodium) 0.5g Powder for solution for Intramuscular Injection.
Ceftriaxone (sodium) 1g Powder for solution for Intramuscular Injection.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Xenor® 0.5 g powder for solution for injection: Each vial contains 0.5 g ceftriaxone (sodium).
Xenor® 1 g powder for solution for injection: Each vial contains 1 g ceftriaxone (sodium).

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Xenor® is powder for solution for injection.

Xenor® 0.5 g: An almost white or yellowish, crystalline powder filled in Clear Moulded Glass Vial Type (I) (Size 10 ml), plugged with Bromobutyl Rubber Stopper (Red) & sealed with Aluminum Cap Flip-Off Light Grey Plastic Top, intended for IM or IV injection.
Xenor ® 1g: An almost white or yellowish, crystalline powder filled in Clear Moulded Glass Vial Type (I) (Size 10 ml), plugged with Bromobutyl Rubber Stopper (Red) & sealed with Aluminum Cap Flip-Off Green Plastic Top, intended for IM or IV injection.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Xenor<sup>&reg;</sup></strong> is indicated for the treatment of the following infections in adults and children including term neonates (from birth):</p><p>Bacterial Meningitis.</p><p>Community acquired pneumonia.</p><p>Hospital acquired pneumonia.</p><p>Acute otitis media.</p><p>Intra-abdominal infections.</p><p>Complicated urinary tract infections (including pyelonephritis).</p><p>Infections of bones and joints.</p><p>Complicated skin and soft tissue infections.</p><p>Gonorrhea.</p><p>Syphilis.</p><p>Bacterial endocarditis.</p><p><strong>Xenor<sup>&reg;</sup></strong> may be used:</p><p>For treatment of acute exacerbations of chronic obstructive pulmonary disease in adults.</p><p>For treatment of disseminated Lyme borreliosis (early (stage II) and late (stage III)) in adults and children including neonates from 15 days of age.</p><p>For Pre-operative prophylaxis of surgical site infections.</p><p>In the management of neutropenic patients with fever that is suspected to be due to a bacterial infection.</p><p>In the treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above.</p><p><strong>Xenor<sup>&reg; </sup></strong>should be co-administered with other antibacterial agents whenever the possible range of causative bacteria would not fall within its spectrum (see section 4.4).</p><p>Consideration should be given to official guidelines on the appropriate use of antibacterial agents.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Posology</strong></p><p>The dose depends on the severity, susceptibility, site and type of infection and on the age and hepato-renal function of the patient.</p><p>The doses recommended in the tables below are the generally recommended doses in these indications. In particularly severe cases, doses at the higher end of the recommended range should be considered.</p><p><strong>Adults and children over 12 years of age (&ge; 50 kg)</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Ceftriaxone</strong></p><p><strong>Dosage*</strong></p></td><td><p><strong>Treatment</strong></p><p><strong>frequency**</strong></p></td><td><p><strong>Indications</strong></p></td></tr><tr><td rowspan="4"><p>1-2 g</p></td><td rowspan="4"><p>Once daily</p></td><td><p>Community acquired pneumonia</p></td></tr><tr><td><p>Acute exacerbations of chronic obstructive pulmonary disease</p></td></tr><tr><td><p>Intra-abdominal infections</p></td></tr><tr><td><p>Complicated urinary tract infections (including pyelonephritis)</p></td></tr><tr><td rowspan="3"><p>2 g</p></td><td rowspan="3"><p>Once daily</p></td><td><p>Hospital acquired pneumonia</p></td></tr><tr><td><p>Complicated skin and soft tissue infections</p></td></tr><tr><td><p>Infections of bones and joints</p></td></tr><tr><td rowspan="3"><p>2-4 g</p></td><td rowspan="3"><p>Once daily</p></td><td><p>Management of neutropenic patients with fever that is suspected to be due to a bacterial infection</p></td></tr><tr><td><p>Bacterial endocarditis</p></td></tr><tr><td><p>Bacterial meningitis</p></td></tr></tbody></table><p>* In documented bacteraemia, the higher end of the recommended dose range should be considered.</p><p>** Twice daily (12 hourly) administration may be considered where doses greater than 2 g daily are administered.</p><p><strong>Indications for adults and children over 12 years of age (&ge; 50 kg) that require specific dosage schedules:</strong></p><p><strong>Acute otitis media</strong></p><p>A single intramuscular dose of <strong>Xenor<sup>&reg;</sup></strong> 1-2 g can be given. Limited data suggest that in cases where the patient is severely ill or previous therapy has failed, ceftriaxone may be effective when given as an intramuscular dose of 1-2 g daily for 3 days.</p><p><strong>Pre-operative prophylaxis of surgical site infections</strong></p><p>2 g as a single pre-operative dose.</p><p><strong>Gonorrhea</strong></p><p>0.5 g as a single intramuscular dose.</p><p><strong>Syphilis</strong></p><p>The generally recommended doses are 0.5 g-1 g once daily increased to 2 g once daily for neurosyphilis for 10-14 days. The dose recommendations in syphilis, including neurosyphilis, are based on limited data. National or local guidance should be taken into consideration.</p><p><strong>Disseminated Lyme borreliosis (early [Stage II] and late [Stage III])</strong></p><p>2 g once daily for 14-21 days. The recommended treatment durations vary and national or local guidelines should be taken into consideration.</p><p><strong>Paediatric population</strong></p><p><strong>Neonates, infants and children 15 days to 12 years of age (&lt; 50&nbsp;kg)</strong></p><p>For children with bodyweight of 50 kg or more, the usual adult dosage should be given.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Ceftriaxone dosage*</strong></p></td><td><p><strong>Treatment frequency**</strong></p></td><td><p><strong>Indications</strong></p></td></tr><tr><td rowspan="4"><p>50-80 mg/kg</p></td><td rowspan="4"><p>Once daily</p></td><td><p>Intra-abdominal infections</p></td></tr><tr><td><p>Complicated urinary tract infections (including pyelonephritis)</p></td></tr><tr><td><p>Community acquired pneumonia</p></td></tr><tr><td><p>Hospital acquired pneumonia</p></td></tr><tr><td rowspan="3"><p>50-100 mg/kg (Max 4 g)</p></td><td rowspan="3"><p>Once daily</p></td><td><p>Complicated skin and soft tissue infections</p></td></tr><tr><td><p>Infections of bones and joints</p></td></tr><tr><td><p>Management of neutropenic patients with fever that is suspected to be due to a bacterial infection</p></td></tr><tr><td><p>80-100 mg/kg (max 4 g)</p></td><td><p>Once daily</p></td><td><p>Bacterial meningitis</p></td></tr><tr><td><p>100 mg/kg</p><p>(max 4 g)</p></td><td><p>Once daily</p></td><td><p>Bacterial endocarditis</p></td></tr></tbody></table><p>* In documented bacteraemia, the higher end of the recommended dose range should be considered.</p><p>** Twice daily (12 hourly) administration may be considered where doses greater than 2 g daily are administered.</p><p><strong>Indications for neonates, infants and children 15 days to 12 years (&lt; 50 kg) that require specific dosage schedules:</strong></p><p><strong>Acute otitis media</strong></p><p>For initial treatment of acute otitis media, a single intramuscular dose of <strong>Xenor<sup>&reg;</sup></strong> 50 mg/kg can be given. Limited data suggest that in cases where the child is severely ill or initial therapy has failed, ceftriaxone may be effective when given as an intramuscular dose of 50 mg/kg daily for 3 days.</p><p><strong>Pre-operative prophylaxis of surgical site infections</strong></p><p>50-80 mg/kg as a single pre-operative dose.</p><p><strong>Syphilis</strong></p><p>The generally recommended doses are 75-100 mg/kg (max 4 g) once daily for 10-14 days. The dose recommendations in syphilis, including neurosyphilis, are based on very limited data. National or local guidance should be taken into consideration.</p><p><strong>Disseminated Lyme borreliosis (early [Stage II] and late [Stage III])</strong></p><p>50-80 mg/kg once daily for 14-21 days. The recommended treatment durations vary and national or local guidelines should be taken into consideration.</p><p><strong>Neonates 0-14 days</strong></p><p><strong>Xenor<sup>&reg;</sup></strong> is contraindicated in premature neonates up to a postmenstrual age of 41 weeks (gestational age + chronological age).</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Ceftriaxone dosage*</strong></p></td><td><p><strong>Treatment frequency</strong></p></td><td><p><strong>Indications</strong></p></td></tr><tr><td rowspan="7"><p>20-50 mg/kg</p></td><td rowspan="7"><p>Once daily</p></td><td><p>Intra-abdominal infections</p></td></tr><tr><td><p>Complicated skin and soft tissue infections</p></td></tr><tr><td><p>Complicated urinary tract infections (including pyelonephritis)</p></td></tr><tr><td><p>Community acquired pneumonia</p></td></tr><tr><td><p>Hospital acquired pneumonia</p></td></tr><tr><td><p>Infections of bones and joints</p></td></tr><tr><td><p>Management of neutropenic patients with fever that is suspected to be due to a bacterial infection</p></td></tr><tr><td rowspan="2"><p>50 mg/kg</p></td><td rowspan="2"><p>Once daily</p></td><td><p>Bacterial meningitis</p></td></tr><tr><td><p>Bacterial endocarditis</p></td></tr></tbody></table><p>* In documented bacteraemia, the higher end of the recommended dose range should be considered.</p><p>A maximum daily dose of 50 mg/kg should not be exceeded.</p><p><strong>Indications for neonates 0-14 days that require specific dosage schedules:</strong></p><p><strong>Acute otitis media</strong></p><p>For initial treatment of acute otitis media, a single intramuscular dose of <strong>Xenor<sup>&reg;</sup></strong> 50 mg/kg can be given.</p><p><strong>Pre-operative prophylaxis of surgical site infections</strong></p><p>20-50 mg/kg as a single pre-operative dose.</p><p><strong>Syphilis</strong></p><p>The generally recommended dose is 50 mg/kg once daily for 10-14 days. The dose recommendations in syphilis, including neurosyphilis, are based on very limited data. National or local guidance should be taken into consideration.</p><p><strong><u>Duration of therapy</u></strong></p><p>The duration of therapy varies according to the course of the disease. As with antibiotic therapy in general, administration of ceftriaxone should be continued for 48-72 hours after the patient has become afebrile or evidence of bacterial eradication has been achieved.</p><p><strong><u>Older people</u></strong></p><p>The dosages recommended for adults require no modification in older people provided that renal and hepatic function is satisfactory.</p><p><strong><u>Patients with hepatic impairment</u></strong></p><p>Available data do not indicate the need for dose adjustment in mild or moderate liver function impairment provided renal function is not impaired.</p><p>There are no study data in patients with severe hepatic impairment (see section 5.2).</p><p><strong><u>Patients with renal impairment</u></strong></p><p>In patients with impaired renal function, there is no need to reduce the dosage of ceftriaxone provided hepatic function is not impaired. Only in cases of preterminal renal failure (creatinine clearance &lt;10 ml/min) should the ceftriaxone dosage not exceed 2 g daily.</p><p>In patients undergoing dialysis no additional supplementary dosing is required following the dialysis. Ceftriaxone is not removed by peritoneal- or haemodialysis. Close clinical monitoring for safety and efficacy is advised.</p><p><strong><u>Patients with severe hepatic and renal impairment</u></strong></p><p>In patients with both severe renal and hepatic dysfunction, close clinical monitoring for safety and efficacy is advised.</p><p><strong><u>Method of administration</u></strong></p><p><strong><u>Intramuscular administration</u></strong></p><p><strong>Xenor<sup>&reg;</sup></strong> can be administered by deep intramuscular injection. Intramuscular injections should be injected well within the bulk of a relatively large muscle and not more than</p><p>1 g should be injected at one site.</p><p>As the solvent used is lidocaine, the resulting solution should never be administered intravenously (see section 4.3). The information in the Summary of Product Characteristics of lidocaine should be considered.</p><p><strong><u>Intravenous administration</u></strong></p><p><strong>Xenor<sup>&reg;</sup></strong> can be administered by intravenous infusion over at least 30 minutes (preferred route) or by slow intravenous injection over 5 minutes. Intravenous intermittent injection should be given over 5 minutes preferably in larger veins. Intravenous doses of 50 mg/kg or more in infants and children up to 12 years of age should be given by infusion. In neonates, intravenous doses should be given over 60 minutes to reduce the potential risk of bilirubin encephalopathy (see section 4.3 and 4.4). Intramuscular administration should be considered when the intravenous route is not possible or less appropriate for the patient. For doses greater than 2 g intravenous administration should be used.</p><p>Ceftriaxone is contraindicated in neonates (&le; 28 days) if they require (or are expected to require) treatment with calcium-containing intravenous solutions, including continuous calcium-containing infusions such as parenteral nutrition, because of the risk of precipitation of ceftriaxone-calcium (see section 4.3).</p><p>Diluents containing calcium, (e.g. Ringer&#39;s solution or Hartmann&#39;s solution), should not be used to reconstitute ceftriaxone vials or to further dilute a reconstituted vial for intravenous administration because a precipitate can form. Precipitation of ceftriaxone-calcium can also occur when ceftriaxone is mixed with calcium-containing solutions in the same intravenous administration line. Therefore, ceftriaxone and calcium-containing solutions must not be mixed or administered simultaneously (see sections 4.3, 4.4 and 6.2).</p><p>For pre-operative prophylaxis of surgical site infections, ceftriaxone should be administered 30-90 minutes prior to surgery.</p><p>For instructions on reconstitution of the medicinal product before administration, see section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
•	Hypersensitivity to ceftriaxone, to any other cephalosporin or to any of the excipients listed in section 6.1.
•	History of severe hypersensitivity (e.g. anaphylactic reaction) to any other type of beta-lactam antibacterial agent (penicillins, monobactams and carbapenems).
Ceftriaxone is contraindicated in:
Premature neonates up to a postmenstrual age of 41 weeks (gestational age + chronological age)*
Full-term neonates (up to 28 days of age):
- With hyperbilirubinaemia, jaundice, or who are hypoalbuminaemic or acidotic because these are conditions in which bilirubin binding is likely to be impaired*
- If they require (or are expected to require) intravenous calcium treatment, or calcium-containing infusions due to the risk of precipitation of a ceftriaxone-calcium salt (see sections 4.4, 4.8 and 6.2).
* In vitro studies have shown that ceftriaxone can displace bilirubin from its serum albumin binding sites leading to a possible risk of bilirubin encephalopathy in these patients.
Contraindications to lidocaine must be excluded before intramuscular injection of ceftriaxone when lidocaine solution is used as a solvent (see section 4.4). See information in the Summary of Product Characteristics of lidocaine, especially contraindications.
Ceftriaxone solutions containing lidocaine should never be administered intravenously.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Hypersensitivity reactions</u></strong></p><p>As with all beta-lactam antibacterial agents, serious and occasionally fatal hypersensitivity reactions have been reported (see section 4.8). In case of severe hypersensitivity reactions, treatment with ceftriaxone must be discontinued immediately and adequate emergency measures must be initiated. Before beginning treatment, it should be established whether the patient has a history of severe hypersensitivity reactions to ceftriaxone, to other cephalosporins or to any other type of beta-lactam agent. Caution should be used if ceftriaxone is given to patients with a history of non-severe hypersensitivity to other beta-lactam agents.</p><p>Severe cutaneous adverse reactions (Stevens Johnson syndrome or Lyell&#39;s syndrome/toxic epidermal necrolysis) have been reported; however, the frequency of these events is not known (see section 4.8).</p><p><strong><u>Interaction with calcium containing products</u></strong></p><p>Cases of fatal reactions with calcium-ceftriaxone precipitates in lungs and kidneys in premature and full-term neonates aged less than 1 month have been described. At least one of them had received ceftriaxone and calcium at different times and through different intravenous lines. In the available scientific data, there are no reports of confirmed intravascular precipitations in patients, other than neonates, treated with ceftriaxone and calcium-containing solutions or any other calcium-containing products.&nbsp;In vitro&nbsp;studies demonstrated that neonates have an increased risk of precipitation of ceftriaxone-calcium compared to other age groups.</p><p>In patients of any age ceftriaxone must not be mixed or administered simultaneously with any calcium-containing intravenous solutions, even via different infusion lines or at different infusion sites. However, in patients older than 28 days of age ceftriaxone and calcium-containing solutions may be administered sequentially one after another if infusion lines at different sites are used or if the infusion lines are replaced or thoroughly flushed between infusions with physiological salt-solution to avoid precipitation. In patients requiring continuous infusion with calcium-containing total parenteral nutrition (TPN) solutions, healthcare professionals may wish to consider the use of alternative antibacterial treatments which do not carry a similar risk of precipitation. If the use of ceftriaxone is considered necessary in patients requiring continuous nutrition, TPN solutions and ceftriaxone can be administered simultaneously, albeit via different infusion lines at different sites. Alternatively, infusion of TPN solution could be stopped for the period of ceftriaxone infusion and the infusion lines flushed between solutions (see sections 4.3, 4.8, 5.2 and 6.2).</p><p><strong><u>Paediatric population</u></strong></p><p>Safety and effectiveness of ceftriaxone in neonates, infants and children have been established for the dosages described under Posology and Method of Administration (see section 4.2). Studies have shown that ceftriaxone, like some other cephalosporins, can displace bilirubin from serum albumin.</p><p><strong>Xenor<sup>&reg;</sup></strong> is contraindicated in premature and full-term neonates at risk of developing bilirubin encephalopathy (see section 4.3).</p><p><strong><u>Immune mediated haemolytic anaemia</u></strong></p><p>An immune mediated haemolytic anaemia has been observed in patients receiving cephalosporin class antibacterials including ceftriaxone (see section 4.8). Severe cases of haemolytic anaemia, including fatalities, have been reported during ceftriaxone treatment in both adults and children.</p><p>If a patient develops anaemia while on ceftriaxone, the diagnosis of a cephalosporin-associated anaemia should be considered and ceftriaxone discontinued until the aetiology is determined.</p><p><strong><u>Long term treatment</u></strong></p><p>During prolonged treatment complete blood count should be performed at regular intervals.</p><p><strong><u>Colitis/Overgrowth of non-susceptible microorganisms</u></strong></p><p>Antibacterial agent-associated colitis and pseudo-membranous colitis have been reported with nearly all antibacterial agents, including ceftriaxone, and may range in severity from mild to life-threatening. Therefore, it is important to consider this diagnosis in patients who present with diarrhea during or subsequent to the administration of ceftriaxone (see section 4.8). Discontinuation of therapy with ceftriaxone and the administration of specific treatment for&nbsp;Clostridium difficile&nbsp;should be considered. Medicinal products that inhibit peristalsis should not be given.</p><p>Superinfections with non-susceptible micro-organisms may occur as with other antibacterial agents.</p><p><strong><u>Severe renal and hepatic insufficiency</u></strong></p><p>In severe renal and hepatic insufficiency, close clinical monitoring for safety and efficacy is advised (see section 4.2).</p><p><strong><u>Interference with serological testing</u></strong></p><p>Interference with Coombs tests may occur, as <strong>Xenor<sup>&reg;</sup></strong> may lead to false-positive test results. <strong>Xenor<sup>&reg;</sup></strong> can also lead to false-positive test results for galactosaemia (see section 4.8).</p><p>Non-enzymatic methods for the glucose determination in urine may give false-positive results. Urine glucose determination during therapy with <strong>Xenor<sup>&reg;</sup></strong> should be done enzymatically (see section 4.8).</p><p>The presence of ceftriaxone may falsely lower estimated blood glucose values obtained with some blood glucose monitoring systems. Please refer to instructions for use for each system. Alternative testing methods should be used if necessary.</p><p><strong><u>Sodium</u></strong></p><p><strong>Xenor<sup>&reg;</sup></strong> contains sodium. This should be taken into consideration in patients on a controlled sodium diet.</p><p><strong><u>Antibacterial spectrum</u></strong></p><p>Ceftriaxone has a limited spectrum of antibacterial activity and may not be suitable for use as a single agent for the treatment of some types of infections unless the pathogen has already been confirmed (see section 4.2). In polymicrobial infections, where suspected pathogens include organisms resistant to ceftriaxone, administration of an additional antibiotic should be considered.</p><p><strong><u>Use of lidocaine</u></strong></p><p>In case a lidocaine solution is used as a solvent,&nbsp;ceftriaxone solutions must only be used for intramuscular injection. Contraindications to lidocaine, warnings and other relevant information as detailed in the Summary of Product Characteristics of lidocaine must be considered before use (see section 4.3). The lidocaine solution should never be administered intravenously.</p><p><strong><u>Biliary lithiasis</u></strong></p><p>When shadows are observed on sonograms, consideration should be given to the possibility of precipitates of calcium ceftriaxone. Shadows, which have been mistaken for gallstones, have been detected on sonograms of the gallbladder and have been observed more frequently at ceftriaxone doses of 1 g per day and above. Caution should be particularly considered in the paediatric population. Such precipitates disappear after discontinuation of ceftriaxone therapy. Rarely precipitates of calcium ceftriaxone have been associated with symptoms. In symptomatic cases, conservative nonsurgical management is recommended and discontinuation of ceftriaxone treatment should be considered by the physician based on specific benefit risk assessment (see section 4.8).</p><p><strong><u>Biliary stasis</u></strong></p><p>Cases of pancreatitis, possibly of biliary obstruction aetiology, have been reported in patients treated with ceftriaxone (see section 4.8). Most patients presented with risk factors for biliary stasis and biliary sludge e.g. preceding major therapy, severe illness and total parenteral nutrition. A trigger or cofactor of <strong>Xenor<sup>&reg;</sup></strong>-related biliary precipitation cannot be ruled out.</p><p><strong><u>Renal lithiasis</u></strong></p><p>Cases of renal lithiasis have been reported, which is reversible upon discontinuation of ceftriaxone (see section 4.8). In symptomatic cases, sonography should be performed. Use in patients with history of renal lithiasis or with hypercalciuria should be considered by the physician based on specific benefit risk assessment.</p><p><strong><u>Jarisch-Herxheimer reaction (JHR)</u></strong></p><p>Some patients with spirochete infections may experience a Jarisch-Herxheimer reaction (JHR) shortly after ceftriaxone treatment is started. JHR is usually a self - limiting condition or can be managed by symptomatic treatment. The antibiotic treatment should not be discontinued if such reaction occurs.</p><p><strong><u>Encephalopathy</u></strong></p><p>Encephalopathy has been reported with the use of ceftriaxone (see section 4.8), particularly in elderly patients with severe renal impairment (see section 4.2) or central nervous system disorders. If ceftriaxone-associated encephalopathy is suspected (e.g. decreased level of consciousness, altered mental state, myoclonus, convulsions), discontinuation of ceftriaxone should be considered.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Calcium-containing diluents, such as Ringer&#39;s solution or Hartmann&#39;s solution, should not be used to reconstitute <strong>Xenor<sup>&reg;</sup></strong> vials or to further dilute a reconstituted vial for intravenous administration because a precipitate can form. Precipitation of ceftriaxone-calcium can also occur when ceftriaxone is mixed with calcium-containing solutions in the same intravenous administration line. Ceftriaxone must not be administered simultaneously with calcium-containing intravenous solutions, including continuous calcium-containing infusions such as parenteral nutrition via a Y-site. However, in patients other than neonates, ceftriaxone and calcium-containing solutions may be administered sequentially of one another if the infusion lines are thoroughly flushed between infusions with a compatible fluid.&nbsp;In vitro&nbsp;studies using adult and neonatal plasma from umbilical cord blood demonstrated that neonates have an increased risk of precipitation of ceftriaxone-calcium (see sections 4.2, 4.3, 4.4, 4.8 and 6.2).</p><p>Concomitant use with oral anticoagulants may increase the anti-vitamin K effect and the risk of bleeding. It is recommended that the International Normalised Ratio (INR) is monitored frequently and the posology of the anti-vitamin K drug adjusted accordingly, both during and after treatment with ceftriaxone (see section 4.8).</p><p>There is conflicting evidence regarding a potential increase in renal toxicity of aminoglycosides when used with cephalosporins. The recommended monitoring of aminoglycoside levels (and renal function) in clinical practice should be closely adhered to in such cases.</p><p>In an&nbsp;in-vitro&nbsp;study antagonistic effects have been observed with the combination of chloramphenicol and ceftriaxone. The clinical relevance of this finding is unknown.</p><p>There have been no reports of an interaction between ceftriaxone and oral calcium-containing products or interaction between intramuscular ceftriaxone and calcium-containing products (intravenous or oral).</p><p>In patients treated with ceftriaxone, the Coombs&#39; test may lead to false-positive test results.</p><p>Ceftriaxone, like other antibiotics, may result in false-positive tests for galactosaemia.</p><p>Likewise, non-enzymatic methods for glucose determination in urine may yield false-positive results. For this reason, glucose level determination in urine during therapy with ceftriaxone should be carried out enzymatically.</p><p>No impairment of renal function has been observed after concurrent administration of large doses of ceftriaxone and potent diuretics (e.g. furosemide).</p><p>Simultaneous administration of probenecid does not reduce the elimination of ceftriaxone.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Pregnancy</u></strong></p><p>Ceftriaxone crosses the placental barrier. There are limited amounts of data from the use of ceftriaxone in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to embryonal/foetal, perinatal and postnatal development (see section 5.3). Ceftriaxone should only be administered during pregnancy and in particular in the first trimester of pregnancy if the benefit outweighs the risk.</p><p><strong><u>Breast-feeding</u></strong></p><p>Ceftriaxone is excreted into human milk in low concentrations but at therapeutic doses of ceftriaxone no effects on the breastfed infants are anticipated. However, a risk of diarrhea and fungal infection of the mucous membranes cannot be excluded. The possibility of sensitisation should be taken into account. A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from ceftriaxone therapy, taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.</p><p><strong><u>Fertility</u></strong></p><p>Reproductive studies have shown no evidence of adverse effects on male or female fertility.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>During treatment with ceftriaxone, undesirable effects may occur (e.g. dizziness), which may influence the ability to drive and use machines (see section 4.8). Patients should be cautious when driving or operating machinery.</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The most frequently reported adverse reactions for ceftriaxone are eosinophilia, leucopenia, thrombocytopenia, diarrhea, rash, and hepatic enzymes increased.</p><p>Data to determine the frequency of ceftriaxone ADRs was derived from clinical trials.</p><p>The following convention has been used for the classification of frequency:</p><p>Very common (&ge; 1/10)</p><p>Common (&ge; 1/100 - &lt; 1/10)</p><p>Uncommon (&ge; 1/1000 - &lt; 1/100)</p><p>Rare (&ge; 1/10000 - &lt; 1/1000)</p><p>Not known (cannot be estimated from the available data)</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>System Organ Class</strong></p></td><td><p><strong>Common</strong></p></td><td><p><strong>Uncommon</strong></p></td><td><p><strong>Rare</strong></p></td><td><p><strong>Not Known<sup>&nbsp;a</sup></strong></p></td></tr><tr><td><p>Infections and infestations</p></td><td><p>&nbsp;</p></td><td><p>Genital fungal infection</p></td><td><p>Pseudo-membranous colitis<sup>b</sup></p></td><td><p>Superinfection<sup>b</sup></p></td></tr><tr><td><p>Blood and lymphatic system disorders</p></td><td><p>Eosinophilia</p><p>Leucopenia</p><p>Thrombocytopenia</p></td><td><p>Granulocytopenia</p><p>Anaemia</p><p>Coagulopathy</p></td><td><p>&nbsp;</p></td><td><p>Haemolytic anaemia<sup>b</sup></p><p>Agranulocytosis</p></td></tr><tr><td><p>Immune system disorders</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>Anaphylactic shock</p><p>Anaphylactic reaction</p><p>Anaphylactoid reaction</p><p>Hypersensitivity<sup>b</sup></p><p>Jarisch-Herxheimer reaction<sup>b</sup></p></td></tr><tr><td><p>Nervous system disorders</p></td><td><p>&nbsp;</p></td><td><p>Headache</p><p>Dizziness</p></td><td><p>Encephalopathy</p></td><td><p>Convulsion</p></td></tr><tr><td><p>Ear and labyrinth disorders</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>Vertigo</p></td></tr><tr><td><p>Respiratory, thoracic and mediastinal disorders</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>Bronchospasm</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Gastrointestinal disorders</p></td><td><p>Diarrhea<sup>b</sup></p><p>Loose stools</p></td><td><p>Nausea</p><p>Vomiting</p></td><td><p>&nbsp;</p></td><td><p>Pancreatitis<sup>b</sup></p><p>Stomatitis</p><p>Glossitis</p></td></tr><tr><td><p>Hepatobiliary disorders</p></td><td><p>Hepatic enzyme increased</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>Gall bladder precipitation<sup>b</sup></p><p>Kernicterus</p></td></tr><tr><td><p>Skin and subcutaneous tissue disorders</p></td><td><p>Rash</p></td><td><p>Pruritus</p></td><td><p>Urticaria</p></td><td><p>Stevens Johnson Syndrome<sup>b</sup></p><p>Toxic epidermal necrolysis<sup>b</sup></p><p>Erythema multiforme</p><p>Acute generalised exanthematous pustulosis</p><p>Drug reaction with eosinophilia and systemic symptoms (DRESS)<sup>b</sup></p></td></tr><tr><td><p>Renal and urinary disorders</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>Haematuria</p><p>Glycosuria</p></td><td><p>Oliguria</p><p>Renal precipitation (reversible)</p></td></tr><tr><td><p>General disorders and administration site conditions</p></td><td><p>&nbsp;</p></td><td><p>Phlebitis</p><p>Injection site pain</p><p>Pyrexia</p></td><td><p>Oedema</p><p>Chills</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Investigations</p></td><td><p>&nbsp;</p></td><td><p>Blood creatinine increased</p></td><td><p>&nbsp;</p></td><td><p>Coombs test false positive<sup>b</sup></p><p>Galactosaemia test false positive<sup>b</sup></p><p>Non enzymatic methods for glucose determination false positive<sup>b</sup></p></td></tr></tbody></table><p>&nbsp;</p><p><sup>a</sup>&nbsp;Based on post-marketing reports. Since these reactions are reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency which is therefore categorised as not known.</p><p><sup>b</sup>&nbsp;See section 4.4</p><p><strong>Description of selected adverse reactions</strong></p><p><strong>Infections and infestations</strong></p><p>Reports of diarrhea following the use of ceftriaxone may be associated with&nbsp;Clostridium difficile. Appropriate fluid and electrolyte management should be instituted (see section 4.4).</p><p><strong>Ceftriaxone-calcium salt precipitation</strong></p><p>Rarely, severe, and in some cases, fatal, adverse reactions have been reported in pre-term and full-term neonates (aged &lt; 28 days) who had been treated with intravenous ceftriaxone and calcium. Precipitations of ceftriaxone-calcium salt have been observed in lung and kidneys post-mortem. The high risk of precipitation in neonates is a result of their low blood volume and the longer half-life of ceftriaxone compared with adults (see sections 4.3, 4.4, and 5.2).</p><p>Cases of ceftriaxone precipitation in the urinary tract have been reported, mostly in children treated with high doses (e.g. &ge; 80 mg/kg/day or total doses exceeding 10 grams) and who have other risk factors (e.g. dehydration, confinement to bed). This event may be asymptomatic or symptomatic, and may lead to ureteric obstruction and postrenal acute renal failure, but is usually reversible upon discontinuation of ceftriaxone (see section 4.4).</p><p>Precipitation of ceftriaxone calcium salt in the gallbladder has been observed, primarily in patients treated with doses higher than the recommended standard dose. In children, prospective studies have shown a variable incidence of precipitation with intravenous application - above 30 % in some studies. The incidence appears to be lower with slow infusion (20 - 30 minutes). This effect is usually asymptomatic, but the precipitations have been accompanied by clinical symptoms such as pain, nausea and vomiting in rare cases. Symptomatic treatment is recommended in these cases. Precipitation is usually reversible upon discontinuation of ceftriaxone (see section 4.4).</p><p><strong>&nbsp;</strong></p><p><strong>To report any side effect(s):</strong></p><p><strong>&bull;Saudi Arabia:</strong></p><p>The National Pharmacovigilance Center (NPC):</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa/</p><p><strong>&bull;United Arab of Emirates:</strong></p><p>Pharmacovigilance and Medical Device Section</p><p>P.O. Box: 1853, Tel: 80011111</p><p>Email: pv@mohap.gov.ae</p><p>Drug Department, Ministry of Health &amp; Prevention</p><p>Dubai-UAE.</p><p><strong>&bull;Other GCC States:</strong></p><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In overdose, the symptoms of nausea, vomiting and diarrhea can occur. Ceftriaxone concentrations cannot be reduced by haemodialysis or peritoneal dialysis. There is no specific antidote. Treatment of overdose should be symptomatic.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antibacterials for systemic use, Third-generation cephalosporins, ATC code: J01DD04.</p><p><strong><u>Mode of action</u></strong></p><p>Ceftriaxone inhibits bacterial cell wall synthesis following attachment to penicillin binding proteins (PBPs). This results in the interruption of cell wall (peptidoglycan) biosynthesis, which leads to bacterial cell lysis and death.</p><p><strong><u>Resistance</u></strong></p><p>Bacterial resistance to ceftriaxone may be due to one or more of the following mechanisms:</p><p>&bull; Hydrolysis by beta-lactamases, including extended-spectrum beta-lactamases (ESBLs), carbapenemases and Amp C enzymes that may be induced or stably derepressed in certain aerobic Gram-negative bacterial species.</p><p>&bull; reduced affinity of penicillin-binding proteins for ceftriaxone.</p><p>&bull; Outer membrane impermeability in Gram-negative organisms.</p><p>&bull; Bacterial efflux pumps.</p><p><strong><u>Susceptibility testing breakpoints</u></strong></p><p>Minimum inhibitory concentration (MIC) breakpoints established by the European Committee on Antimicrobial Susceptibility Testing (EUCAST) are as follows:</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2"><p><strong>Pathogen</strong></p></td><td colspan="2"><p><strong>Dilution Test</strong></p><p><strong>(MIC, mg/L)</strong></p></td></tr><tr><td><p><strong>Susceptible</strong></p></td><td><p><strong>Resistant</strong></p></td></tr><tr><td><p><em>Enterobacteriaceae</em></p></td><td><p>&le; 1</p></td><td><p>&gt; 2</p></td></tr><tr><td><p><em>Staphylococcus</em>&nbsp;spp.</p></td><td><p>a.</p></td><td><p>a.</p></td></tr><tr><td><p><em>Streptococcus&nbsp;</em>spp.</p><p>(Groups A, B, C and G)</p></td><td><p>b.</p></td><td><p>b.</p></td></tr><tr><td><p><em>Streptococcus pneumoniae</em></p></td><td><p>&le; 0.5<sup>c.</sup></p></td><td><p>&gt; 2</p></td></tr><tr><td><p>Viridans group&nbsp;<em>Streptococci</em></p></td><td><p>&le;0.5</p></td><td><p>&gt;0.5</p></td></tr><tr><td><p><em>Haemophilus influenzae</em></p></td><td><p>&le; 0.12<sup>c.</sup></p></td><td><p>&gt; 0.12</p></td></tr><tr><td><p><em>Moraxella catarrhalis</em></p></td><td><p>&le; 1</p></td><td><p>&gt; 2</p></td></tr><tr><td><p><em>Neisseria gonorrhoeae</em></p></td><td><p>&le; 0.12</p></td><td><p>&gt; 0.12</p></td></tr><tr><td><p><em>Neisseria meningitidis</em></p></td><td><p>&le; 0.12<sup>&nbsp;c.</sup></p></td><td><p>&gt; 0.12</p></td></tr><tr><td><p>Non-species related</p></td><td><p>&le; 1<sup>d.</sup></p></td><td><p>&gt; 2</p></td></tr></tbody></table><p>a. Susceptibility inferred from cefoxitin susceptibility.</p><p>b. Susceptibility inferred from penicillin susceptibility.</p><p>c. Isolates with a ceftriaxone MIC above the susceptible breakpoint are rare and, if found, should be re-tested and, if confirmed, should be sent to a reference laboratory.</p><p>d. Breakpoints apply to a daily intravenous dose of 1 g x 1 and a high dose of at least</p><p>2 g x 1.</p><p><strong><u>Clinical efficacy against specific pathogens</u></strong></p><p>The prevalence of acquired resistance may vary geographically and with time for selected species and local information on resistance is desirable, particularly when treating severe infections. As necessary, expert advice should be sought when the local prevalence of resistance is such that the utility of ceftriaxone in at least some types of infections is questionable.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Commonly susceptible species</strong></p></td></tr><tr><td><p><u>Gram-positive aerobes</u></p><p><em>Staphylococcus aureus</em>&nbsp;(methicillin-susceptible)<sup>&pound;</sup></p><p>Staphylococci coagulase-negative (methicillin-susceptible)<sup>&pound;</sup></p><p><em>Streptococcus pyogenes</em>&nbsp;(Group A)</p><p><em>Streptococcus agalactiae</em>&nbsp;(Group B)</p><p><em>Streptococcus pneumoniae</em></p><p>Viridans Group&nbsp;<em>Streptococci</em></p><p><u>Gram-negative aerobes</u></p><p><em>Borrelia burgdorferi</em></p><p><em>Haemophilus influenzae</em></p><p><em>Haemophilus parainfluenzae</em></p><p><em>Moraxella&nbsp;catarrhalis</em></p><p><em>Neisseria&nbsp;gonorrhoea</em></p><p><em>Neisseria meningitidis</em></p><p><em>Proteus&nbsp;mirabilis</em></p><p><em>Providencia</em>&nbsp;spp</p><p><em>Treponema pallidum</em></p></td></tr><tr><td><p><strong>Species for which acquired resistance may be a problem</strong></p></td></tr><tr><td><p><u>Gram-positive aerobes</u></p><p><em>Staphylococcus epidermidis<sup>+</sup></em></p><p><em>Staphylococcus haemolyticus<sup>+</sup></em></p><p><em>Staphylococcus hominis<sup>+</sup></em></p><p><u>Gram-negative aerobes</u></p><p><em>Citrobacter&nbsp;freundii</em></p><p><em>Enterobacter aerogenes</em></p><p><em>Enterobacter cloacae</em></p><p><em>Escherichia coli<sup>%</sup></em></p><p><em>Klebsiella pneumoniae<sup>%</sup></em></p><p><em>Klebsiella oxytoca<sup>%</sup></em></p><p><em>Morganella&nbsp;morganii</em></p><p><em>Proteus vulgaris</em></p><p><em>Serratia&nbsp;marcescens</em></p><p><u>Anaerobes</u></p><p><em>Bacteroides&nbsp;</em>spp<em>.</em></p><p><em>Fusobacterium&nbsp;</em>spp.</p><p><em>Peptostreptococcus&nbsp;</em>spp.</p><p><em>Clostridium perfringens</em></p></td></tr><tr><td><p><strong>Inherently resistant organisms</strong></p></td></tr><tr><td><p><u>Gram-positive aerobes</u></p><p><em>Enterococcus&nbsp;</em>spp.</p><p><em>Listeria monocytogenes</em></p><p><u>Gram-negative aerobes</u></p><p><em>Acinetobacter baumannii</em></p><p><em>Pseudomonas aeruginosa</em></p><p><em>Stenotrophomonas maltophilia</em></p><p><u>Anaerobes</u></p><p><em>Clostridium difficile</em></p><p><u>Others:</u></p><p><em>Chlamydia&nbsp;</em>spp.</p><p><em>Chlamydophila</em>&nbsp;spp.</p><p><em>Mycoplasma</em>&nbsp;spp.</p><p><em>Legionella</em>&nbsp;spp.</p><p><em>Ureaplasma urealyticum</em></p></td></tr></tbody></table><p>&pound; All methicillin-resistant staphylococci are resistant to ceftriaxone.</p><p><sup>+&nbsp;</sup>Resistance rates &gt;50% in at least one region</p><p><sup>%&nbsp;</sup>ESBL producing strains are always resistant</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Absorption</u></strong></p><p><strong><u>Intramuscular administration</u></strong></p><p>Following intramuscular injection, mean peak plasma ceftriaxone levels are approximately half those observed after intravenous administration of an equivalent dose. The maximum plasma concentration after a single intramuscular dose of 1 g is about 81 mg/l and is reached in 2 - 3 hours after administration.</p><p>The area under the plasma concentration-time curve after intramuscular administration is equivalent to that after intravenous administration of an equivalent dose.</p><p><strong><u>Intravenous administration</u></strong></p><p>After intravenous bolus administration of ceftriaxone 0.5 g and 1 g, mean peak plasma ceftriaxone levels are approximately 120 and 200 mg/l respectively. After intravenous infusion of ceftriaxone 0.5 g, 1 g and 2 g, the plasma ceftriaxone levels are approximately 80, 150 and 250 mg/l respectively.</p><p><strong><u>Distribution</u></strong></p><p>The volume of distribution of ceftriaxone is 7-12 l. Concentrations well above the minimal inhibitory concentrations of most relevant pathogens are detectable in tissue including lung, heart, biliary tract/liver, tonsil, middle ear and nasal mucosa, bone, and in cerebrospinal, pleural, prostatic and synovial fluids. An 8 - 15 % increase in mean peak plasma concentration (Cmax) is seen on repeated administration; steady state is reached in most cases within 48 - 72 hours depending on the route of administration.</p><p><strong><u>Penetration into particular tissues</u></strong></p><p>Ceftriaxone penetrates the meninges. Penetration is greatest when the meninges are inflamed. Mean peak ceftriaxone concentrations in CSF in patients with bacterial meningitis are reported to be up to 25% of plasma levels compared to 2% of plasma levels in patients with uninflamed meninges. Peak ceftriaxone concentrations in CSF are reached approximately 4-6 hours after intravenous injection. Ceftriaxone crosses the placental barrier and is excreted in the breast milk at low concentrations (see section 4.6).</p><p><strong><u>Protein binding</u></strong></p><p>Ceftriaxone is reversibly bound to albumin. Plasma protein binding is about 95 % at plasma concentrations below 100 mg/l. Binding is saturable and the bound portion decreases with rising concentration (up to 85 % at a plasma concentration of 300 mg/l).</p><p><strong><u>Biotransformation</u></strong></p><p>Ceftriaxone is not metabolised systemically; but is converted to inactive metabolites by the gut flora.</p><p><strong><u>Elimination</u></strong></p><p>Plasma clearance of total ceftriaxone (bound and unbound) is 10-22 ml/min. Renal clearance is 5-12 ml/min. 50-60 % of ceftriaxone is excreted unchanged in the urine, primarily by glomerular filtration, while 40-50 % is excreted unchanged in the bile. The elimination half-life of total ceftriaxone in adults is about 8 hours.</p><p><strong><u>Patients with renal or hepatic impairment</u></strong></p><p>In patients with renal or hepatic dysfunction, the pharmacokinetics of ceftriaxone are only minimally altered with the half-life slightly increased (less than two fold), even in patients with severely impaired renal function.</p><p>The relatively modest increase in half-life in renal impairment is explained by a compensatory increase in non-renal clearance, resulting from a decrease in protein binding and corresponding increase in non-renal clearance of total ceftriaxone.</p><p>In patients with hepatic impairment, the elimination half-life of ceftriaxone is not increased, due to a compensatory increase in renal clearance. This is also due to an increase in plasma free fraction of ceftriaxone contributing to the observed paradoxical increase in total drug clearance, with an increase in volume of distribution paralleling that of total clearance.</p><p><strong><u>Older people</u></strong></p><p>In older people aged over 75 years the average elimination half-life is usually two to three times that of young adults.</p><p><strong><u>Paediatric population</u></strong></p><p>The half-life of ceftriaxone is prolonged in neonates. From birth to 14 days of age, the levels of free ceftriaxone may be further increased by factors such as reduced glomerular filtration and altered protein binding. During childhood, the half-life is lower than in neonates or adults.</p><p>The plasma clearance and volume of distribution of total ceftriaxone are greater in neonates, infants and children than in adults.</p><p><strong><u>Linearity/non-linearity</u></strong></p><p>The pharmacokinetics of ceftriaxone are non-linear and all basic pharmacokinetic parameters, except the elimination half-life, are dose dependent if based on total drug concentrations, increasing less than proportionally with dose. Non-linearity is due to saturation of plasma protein binding and is therefore observed for total plasma ceftriaxone but not for free (unbound) ceftriaxone.</p><p><strong><u>Pharmacokinetic/pharmacodynamic relationship</u></strong></p><p>As with other beta-lactams, the pharmacokinetic-pharmacodynamic index demonstrating the best correlation with&nbsp;in vivo efficacy is the percentage of the dosing interval that the unbound concentration remains above the minimum inhibitory concentration (MIC) of ceftriaxone for individual target species (i.e. %T &gt; MIC).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is evidence from animal studies that high doses of ceftriaxone calcium salt led to formation of concrements and precipitates in the gallbladder of dogs and monkeys, which proved to be reversible. Animal studies produced no evidence of toxicity to reproduction and genotoxicity. Carcinogenicity studies on ceftriaxone were not conducted.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>None.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Based on literature reports, ceftriaxone is not compatible with amsacrine, vancomycin, fluconazole and aminoglycosides.</p><p>Solutions containing ceftriaxone should not be mixed with or added to other agents except those mentioned in section 6.6. In particular diluents containing calcium, (e.g. Ringer&#39;s solution, Hartmann&#39;s solution) should not be used to reconstitute ceftriaxone vials or to further dilute a reconstituted vial for intravenous administration because a precipitate can form. Ceftriaxone must not be mixed or administered simultaneously with calcium containing solutions including total parenteral nutrition (see section 4.2, 4.3, 4.4 and 4.8).</p><p>If treatment with a combination of another antibiotic with <strong>Xenor<sup>&reg;</sup></strong> intended, administration should not occur in the same syringe or in the same infusion solution.</p><p>This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years.
After reconstitution and dilution:
Chemical and physical in-use stability of the reconstituted product has been demonstrated for at least 6 hours at or below 25 °C or 24 hours at 2-8 °C.
From a microbiological point of view, the product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would not be longer than the times stated above for the chemical and physical in-use stability.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C, protected from light.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Xenor</strong><strong><sup>&reg;</sup></strong><strong> 0.5g: </strong>An almost white or yellowish, crystalline powder filled in Clear Moulded Glass Vial Type (I) (Size 10 ml), plugged with Bromobutyl Rubber Stopper (Red) &amp; sealed with Aluminum Cap Flip-Off Light Grey Plastic Top, intended for IM or IV injection.</p><p><strong>Xenor</strong><strong> </strong><strong><sup>&reg;</sup></strong><strong> 1g:</strong> An almost white or yellowish, crystalline powder filled in Clear Moulded Glass Vial Type (I) (Size 10 ml), plugged with Bromobutyl Rubber Stopper (Red) &amp; sealed with Aluminum Cap Flip-Off Green Plastic Top, intended for IM or IV injection.</p><p><strong>Pack size:</strong></p><p><strong>Xenor<sup>&reg;</sup> 0.5 g IM/IV: </strong>One pack of 10 vials each, containing 0.5 g ceftriaxone (Sodium).</p><p><strong>Xenor<sup>&reg;</sup> 1 g IM/IV: </strong>One pack of 10 vials each, containing 1 g ceftriaxone (Sodium).</p><p><strong>Xenor<sup>&reg;</sup> 0.5 g IM:</strong> One pack of 1 vial each, containing 0.5 g ceftriaxone (Sodium) +</p><p>1 ampoule 5 ml 1% lidocaine HCl solution.</p><p><strong>Xenor<sup>&reg;</sup> 1 g IM:</strong> One pack of 1 vial each, containing 1 g ceftriaxone (Sodium) +</p><p>1 ampoule 5 ml 1% lidocaine HCl solution.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Concentrations for the intravenous injection: 100 mg/ml,</p><p>Concentrations for the intravenous infusion: 50 mg/ml.</p><p><strong>Preparation of solutions for injection and infusion</strong></p><p>The use of freshly prepared solutions is recommended. For storage conditions of the reconstituted medicinal product, see section 6.3.</p><p><strong>Xenor<sup>&reg;</sup></strong> should not be mixed in the same syringe with any drug other than 1% Lidocaine Hydrochloride solution (for intramuscular injection only).</p><p>The infusion line should be flushed after each administration.</p><p><strong><u>&nbsp;</u></strong></p><p><u>2 g</u><u> dose from<strong> Xenor<sup>&reg;</sup></strong></u><u> powder for solution for injection or infusion</u></p><p>For IV infusion 2 g of ceftriaxone (2 vials of 1 g <strong>Xenor<sup>&reg;</sup></strong>) is dissolved in 40 ml of one of the following calcium-free infusion fluids: Sodium chloride 0.9%, sodium chloride 0.45% &nbsp;and dextrose 2.5%, dextrose 5%, dextrose 10%, dextran 70 (6%) in dextrose 5%, hydroxyethly-starch-6 10%, water for injections. The infusion should be administered over at least 30 minutes. See also the information in section 6.2.</p><p>In neonates, intravenous doses should be given over 60 minutes to reduce the potential risk of bilirubin encephalopathy.</p><p><u>&nbsp;</u></p><p><strong><u>Xenor<sup>&reg;</sup></u></strong><u> 1 g powder for solution for injection or infusion</u></p><p>For IV injection 1 g <strong>Xenor<sup>&reg; </sup></strong>is dissolved in 10 ml of water for injections. The injection should be administered over 5 minutes, directly into the vein or via the tubing of an intravenous infusion.</p><p>For IM injection 1 g <strong>Xenor<sup>&reg; </sup></strong>is dissolved in 3.5 ml of 1% Lidocaine Hydrochloride solution. The solution should be administered by deep intramuscular injection. Dosages greater than 1 g should be divided and injected at more than one site.</p><p><u>&nbsp;</u></p><p><strong><u>Xenor<sup>&reg; </sup></u></strong><u>0.5 g powder for solution for injection</u></p><p>For IV injection 0.5 g <strong>Xenor<sup>&reg; </sup></strong>is dissolved in 5 ml of water for injections. The injection should be administered over 5 minutes, directly into the vein or via the tubing of an intravenous infusion.</p><p>For IM injection 0.5 g <strong>Xenor<sup>&reg; </sup></strong>is dissolved in 2 ml of 1% lidocaine hydrochloride solution. The solution should be administered by deep intramuscular injection. Dosages greater than 1 g should be divided and injected at more than one site.</p><p>Any unused product or waste material should be disposed of in accordance with local requirements.</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Pharma International Company
Amman - Jordan
Tel: 00962-6-5158890 / 5157893 
Fax: 00962-6-5154753
Email: marketing@pic-jo.com
	

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                03/2021
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>